# PDUFA dates March 2026: FDA calendar and catalysts

Canonical: https://sec-api.dev/fda-calendar/2026-03

> 399 FDA catalysts are dated in March 2026, including 10 PDUFA dates.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What PDUFA dates are in March 2026?

PDUFA dates in March 2026: BRISTOL MYERS SQUIBB CO (BMY) on March 6, 2026; deramiocel (CAPR) on March 10, 2026; reproxalap (ALDX) on March 16, 2026; Aldeyra Therapeutics, Inc. (ALDX) on March 16, 2026; RM-718 (RYTM) on March 20, 2026; IMCIVREE® (setmelanotide, RYTM) on March 20, 2026; and 4 more. [Calendar and source filings](https://sec-api.dev/fda-calendar/2026-03)

Source: SEC Form 10-K, accession 0000014272-26-000004, https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/bmy-20251231.htm (retrieved 2026-11-12). Last confirmed 2026-02-11. Cite: https://sec-api.dev/fda-calendar/2026-03#answer

## PDUFA dates in March 2026

Data as of November 16, 2026.

| PDUFA date | Company | Ticker | Drug | Indication | Source |
| --- | --- | --- | --- | --- | --- |
| March 6, 2026 | BRISTOL MYERS SQUIBB CO | BMY |  |  | [SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/bmy-20251231.htm) |
| March 10, 2026 | CAPRICOR THERAPEUTICS, INC. | CAPR | deramiocel |  | [SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1133869/000110465926025657/capr-20260310x8k.htm) |
| March 16, 2026 | Aldeyra Therapeutics, Inc. | ALDX | reproxalap |  | [SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1341235/000119312526109511/aldx-20260317.htm) |
| March 16, 2026 | Aldeyra Therapeutics, Inc. | ALDX |  |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1341235/000119312525319638/aldx-ex99_1.htm) |
| March 20, 2026 | RHYTHM PHARMACEUTICALS, INC. | RYTM | RM-718 |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000162828026018211/ex992rytm20260313emanate.htm) |
| March 20, 2026 | RHYTHM PHARMACEUTICALS, INC. | RYTM | IMCIVREE® (setmelanotide) | acquired hypothalamic obesity | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000110465926021801/tm267699d1_ex99-1.htm) |
| March 24, 2026 | GSK plc | GSK | linerixibat |  | [SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1131399/000165495426002008/a8361v.htm) |
| March 28, 2026 | ROCKET PHARMACEUTICALS, INC. | RCKT | KRESLADI (marnetegragene autotemcel) |  | [Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1281895/000114036126006981/ef20066645_ex99-1.htm) |
| March 28, 2026 | ROCKET PHARMACEUTICALS, INC. | RCKT |  |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1281895/000119312526458320/rckt-20260930.htm) |
| March 31, 2026 | Fortress Biotech, Inc. | FBIO | ZYCUBO (CUTX-101) |  | [SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1429260/000110465926126531/fbio-20260930x10q.htm) |

## All catalysts in March 2026

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| March 1, 2026 | [SEP-631 trial start](https://sec-api.dev/pdufa/sep-631) | SEPN |  | completed | "Other than SEP-631, for which we presented data from the Phase 1 clinical trial at the AAAAI annual meeting on March 1, 2026, and SEP-479, for which we initiated our Phase 1 clinical trial in April 2026, our product candidates and development programs, including SEP-204, which we selected as a development candidate in November 2026, are in preclinical development or in the drug discovery stages." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1984086/000119312526453564/sepn-20260930.htm)) |
| March 2, 2026 | [Nuvation Bio Inc. earnings report](https://sec-api.dev/companies/nuvb/catalysts) | NUVB |  | completed | "Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1811063/000119312526085474/d15383dex991.htm)) |
| March 2, 2026 | [Biohaven Ltd. earnings report](https://sec-api.dev/companies/bhvn/catalysts) | BHVN |  | completed | "Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1935979/000193597926000022/a2025q4bhvnearningsprex991.htm)) |
| March 2, 2026 | [Xeris Biopharma Holdings, Inc. earnings report](https://sec-api.dev/companies/xers/catalysts) | XERS |  | completed | "CHICAGO, IL; March 2, 2026 - Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provides financial guidance for full year 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1867096/000186709626000012/exh991q42025earningsrelease.htm)) |
| March 2, 2026 | [Sionna Therapeutics, Inc. earnings report](https://sec-api.dev/companies/sion/catalysts) | SION |  | completed | "Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2036042/000162828026012993/sionfy4q25earningsrelease_.htm)) |
| March 2, 2026 | [Zymeworks Inc. earnings report](https://sec-api.dev/companies/zyme/catalysts) | ZYME |  | completed | "Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1937653/000193765326000013/ex991q42025_earningsxrelea.htm)) |
| March 2, 2026 | [Tyra Biosciences, Inc. earnings report](https://sec-api.dev/companies/tyra/catalysts) | TYRA |  | completed | "Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1863127/000119312526085399/tyra-ex99_1.htm)) |
| March 2, 2026 | [HARROW, INC. earnings report](https://sec-api.dev/companies/hrow/catalysts) | HROW |  | completed | "Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1360214/000149315226008552/ex99-1.htm)) |
| March 2, 2026 | [UniQure N.V. earnings report](https://sec-api.dev/companies/qure/catalysts) | QURE |  | completed | "Exhibit 99.1 uniQure Announces 2025 Financial Results and Provides Recent Company" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021890/qure-20260302xex99d1.htm)) |
| March 2, 2026 | [CalciMedica, Inc. earnings report](https://sec-api.dev/companies/calc/catalysts) | CALC |  | completed | "CalciMedica Reports 2025 Financial Results and Provides Clinical Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534133/000119312526086658/ck0001534133-ex99_1.htm)) |
| March 2, 2026 | [UroGen Pharma Ltd. earnings report](https://sec-api.dev/companies/urgn/catalysts) | URGN |  | completed | "UroGen Announces ZUSDURITM Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1668243/000143774926006233/ex_925621.htm)) |
| March 2, 2026 | [Dyne Therapeutics, Inc. earnings report](https://sec-api.dev/companies/dyn/catalysts) | DYN |  | completed | "Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818794/000119312526084207/dyn-ex99_1.htm)) |
| March 2, 2026 | [Avalglucosidase alfa primary completion](https://sec-api.dev/pdufa/avalglucosidase-alfa) | SNY | Glycogen Storage Disease Type II | completed | "NCT04910776 (Clinical Study for Treatment-naïve IOPD Babies to Evaluate Efficacy and Safety of ERT With Avalglucosidase Alfa): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-03-02 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04910776)) |
| March 2, 2026 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Muscle Invasive Bladder Cancer | completed | "NCT04960709 (Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-03-02 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04960709)) |
| March 2, 2026 | [Adcirca® (tadalafil) primary completion](https://sec-api.dev/pdufa/tadalafil) | SNY | Erectile Dysfunction | completed | "NCT06805513 (Actual Use Trial of Tadalafil 5 mg): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-03-02 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06805513)) |
| March 3, 2026 | [Passage BIO, Inc. earnings report](https://sec-api.dev/companies/pasg/catalysts) | PASG |  | completed | "PASSAGE BIO REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES RECENT BUSINESS HIGHLIGHTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787297/000110465926022539/pasg-20260303xex99d1.htm)) |
| March 3, 2026 | [Arcturus Therapeutics Holdings Inc. earnings report](https://sec-api.dev/companies/arct/catalysts) | ARCT |  | completed | "Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1768224/000119380526000214/e665201_ex99-1.htm)) |
| March 3, 2026 | [ANAPTYSBIO, INC earnings report](https://sec-api.dev/companies/anab/catalysts) | ANAB |  | completed | "Announces Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1370053/000119312526088239/anab-ex99_1.htm)) |
| March 3, 2026 | [Scholar Rock Holding Corp earnings report](https://sec-api.dev/companies/srrk/catalysts) | SRRK |  | completed | "Scholar Rock Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1727196/000110465926022547/srrk-20260303xex99d1.htm)) |
| March 3, 2026 | [Sana Biotechnology, Inc. earnings report](https://sec-api.dev/companies/sana/catalysts) | SANA |  | completed | "Sana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1770121/000119312526088203/sana-ex99_1.htm)) |
| March 3, 2026 | [ELUTIA INC. earnings report](https://sec-api.dev/companies/elut/catalysts) | ELUT |  | completed | "Elutia Reports Fourth Quarter and Full Year 2025 Financial Results; Initiates NXT-41 Regulatory Process" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1708527/000110465926026398/elut-20260303xex99d1.htm)) |
| March 3, 2026 | [Enliven Therapeutics, Inc. earnings report](https://sec-api.dev/companies/elvn/catalysts) | ELVN |  | completed | "Enliven Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1672619/000119312526088195/elvn-ex99_1.htm)) |
| March 3, 2026 | [Boundless Bio, Inc. earnings report](https://sec-api.dev/companies/bold/catalysts) | BOLD |  | completed | "Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1782303/000119312526097535/bold-ex99_1.htm)) |
| March 3, 2026 | [Evolus, Inc. earnings report](https://sec-api.dev/companies/eols/catalysts) | EOLS |  | completed | "Evolus Reports Fourth Quarter and Full-Year 2025 Financial Results; Delivers Sixth Consecutive Year of Double-Digit Growth and Expects Sustainable Profitability1 Beginning in 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1570562/000162828026013872/q42025eolsex991.htm)) |
| March 3, 2026 | [Amylyx Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/amlx/catalysts) | AMLX |  | completed | "Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1658551/000119312526086629/amlx-ex99_1.htm)) |
| March 3, 2026 | [RIGEL PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/rigl/catalysts) | RIGL |  | completed | "SOUTH SAN FRANCISCO, Calif., March 3, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today reported financial results for the fourth quarter and year ended December 31, 2025, including sales of TAVALISSE® (fostamatinib disodium hexahydrate), GAVRETO® (pralsetinib) and REZLIDHIA® (olutasidenib), and recent business progress." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1034842/000103484226000016/rigl-20260303xex991q42025r.htm)) |
| March 3, 2026 | [Immunome Inc. earnings report](https://sec-api.dev/companies/imnm/catalysts) | IMNM |  | completed | "Immunome Reports Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1472012/000119312526088141/imnm-ex99_1.htm)) |
| March 3, 2026 | [Cryoport, Inc. earnings report](https://sec-api.dev/companies/cyrx/catalysts) | CYRX |  | completed | "Tennessee, March 3, 2026, - Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its fourth quarter (Q4) and year ended (FY) December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1124524/000110465926022940/tm267876d1_ex99-1.htm)) |
| March 3, 2026 | [LISRAYA™ (brepocitinib) NDA/BLA acceptance](https://sec-api.dev/pdufa/brepocitinib) | ROIV | dermatomyositis filed | completed | "On March 3, 2026, Roivant Sciences Ltd. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration has accepted the New Drug Application ("NDA") for brepocitinib for the treatment of dermatomyositis filed by the Company's subsidiary, Priovant Therapeutics, and has granted the NDA Priority Review." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1635088/000114036126007447/ef20066998_8k.htm)) |
| March 3, 2026 | [Prime Medicine, Inc. earnings report](https://sec-api.dev/companies/prme/catalysts) | PRME |  | completed | "Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1894562/000162828026013565/fy20258-kex991xpressrelease.htm)) |
| March 3, 2026 | [Aquestive Therapeutics, Inc. earnings report](https://sec-api.dev/companies/aqst/catalysts) | AQST |  | completed | "Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1398733/000139873326000016/aqst-q425xex991earningsrel.htm)) |
| March 3, 2026 | [JAKAFI (ruxolitinib) primary completion](https://sec-api.dev/pdufa/ruxolitinib) | INCY | Leukemia | completed | "NCT02723994 (A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-03-03 (ACTUAL); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02723994)) |
| March 4, 2026 | [Keros Therapeutics, Inc. earnings report](https://sec-api.dev/companies/kros/catalysts) | KROS |  | completed | "Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1664710/000166471026000017/exhibit991fy2025.htm)) |
| March 4, 2026 | [Ocugen, Inc. earnings report](https://sec-api.dev/companies/ocgn/catalysts) | OCGN |  | completed | "Pa, March 4, 2026 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today reported fourth quarter and full year 2025 financial results along with a general business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1372299/000110465926023288/tm267731d1_ex99-1.htm)) |
| March 4, 2026 | [PepGen Inc. earnings report](https://sec-api.dev/companies/pepg/catalysts) | PEPG |  | completed | "PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1835597/000119312526091503/pepg-ex99_1.htm)) |
| March 4, 2026 | [Denileukin topline data readout](https://sec-api.dev/pdufa/denileukin) | CTOR | high risk relapsed or refractory diffuse large B cell lymphoma | completed, positive | "On March 4, 2026, we issued a press release announced positive topline safety and efficacy results from an investigator initiated Phase 1 trial evaluating LYMPHIR™ (E7777, denileukin diftitox cxdl) administered prior to commercial CD19 directed CAR T therapy in patients with high risk relapsed or refractory diffuse large B cell lymphoma (DLBCL)." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1851484/000121390026023440/ea0277423-8k_citius.htm)) |
| March 4, 2026 | [Cellectar Biosciences, Inc. earnings report](https://sec-api.dev/companies/clrb/catalysts) | CLRB |  | completed | "Reports Financial Results for Year Ended 2025 and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1279704/000110465926023169/tm267955d1_ex99-1.htm)) |
| March 4, 2026 | [LYMPHIR (lymphir) topline data readout](https://sec-api.dev/pdufa/lymphir) | CTOR | high risk relapsed or refractory diffuse large B cell lymphoma | completed, positive | "On March 4, 2026, we announced positive topline safety and efficacy results from an investigator-initiated Phase 1 trial evaluating LYMPHIR administered prior to commercial CD19 directed" ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1851484/000121390026090184/ea0301678-10q_citius.htm)) |
| March 4, 2026 | [TScan Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tcrx/catalysts) | TCRX |  | completed | "TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1783328/000119312526089871/tcrx-ex99_1.htm)) |
| March 4, 2026 | [Denileukin trial start](https://sec-api.dev/pdufa/denileukin) | CTOR | high risk relapsed or refractory diffuse large B cell lymphoma | completed | "On March 4, 2026, we issued a press release announced positive topline safety and efficacy results from an investigator initiated Phase 1 trial evaluating LYMPHIR™ (E7777, denileukin diftitox cxdl) administered prior to commercial CD19 directed CAR T therapy in patients with high risk relapsed or refractory diffuse large B cell lymphoma (DLBCL)." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1851484/000121390026023440/ea0277423-8k_citius.htm)) |
| March 4, 2026 | [OmniAb, Inc. earnings report](https://sec-api.dev/companies/oabi/catalysts) | OABI |  | completed | "OmniAb Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1846253/000184625326000006/a2025q4ex991.htm)) |
| March 4, 2026 | [ZEVRA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/zvra/catalysts) | ZVRA |  | completed | "Zevra Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1434647/000143464726000009/zvra-20260309xex991earnings.htm)) |
| March 4, 2026 | [Mirikizumab primary completion](https://sec-api.dev/pdufa/mirikizumab) | LLY | Ulcerative Colitis | completed | "NCT03519945 (A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-03-04 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03519945)) |
| March 2026 | [Truqap (capivasertib) primary completion](https://sec-api.dev/pdufa/capivasertib) | AZN | Prostate Cancer | delayed | "NCT05348577 (Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-03-04 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05348577)) |
| March 4, 2026 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Type 2 Diabetes | completed | "NCT06221969 (A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-03-04 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06221969)) |
| March 4, 2026 | [Emvistegrast primary completion](https://sec-api.dev/pdufa/emvistegrast) | GILD | Ulcerative Colitis | completed | "NCT06290934 (Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-03-04 (ACTUAL); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06290934)) |
| March 4, 2026 | [VRDN-003 primary completion](https://sec-api.dev/pdufa/vrdn-003) | VRDN | Thyroid Eye Disease | completed | "NCT06625398 (An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-03-04 (ACTUAL); Lead Sponsor Viridian Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06625398)) |
| March 5, 2026 | [Invivyd, Inc. earnings report](https://sec-api.dev/companies/ivvd/catalysts) | IVVD |  | completed | "Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1832038/000119312526092528/d118119dex991.htm)) |
| March 5, 2026 | [Tango Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tngx/catalysts) | TNGX |  | completed | "Tango Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819133/000119312526092535/tngx-ex99_1.htm)) |
| March 5, 2026 | [Climb Bio, Inc. earnings report](https://sec-api.dev/companies/clym/catalysts) | CLYM |  | completed | "Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1768446/000119312526092520/clym-ex99_1.htm)) |
| March 5, 2026 | [LEXICON PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/lxrx/catalysts) | LXRX |  | completed | "The Woodlands, Texas, March 5, 2026 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months and year ended December 31, 2025, and provided an update on key corporate milestones and accomplishments." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1062822/000106282226000047/pressreleaseearningsq403-0.htm)) |
| March 5, 2026 | [Caribou Biosciences, Inc. earnings report](https://sec-api.dev/companies/crbu/catalysts) | CRBU |  | completed | "Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1619856/000161985626000007/crbu-20260305xexx991.htm)) |
| March 5, 2026 | [ArriVent BioPharma, Inc. earnings report](https://sec-api.dev/companies/avbp/catalysts) | AVBP |  | completed | "ArriVent BioPharma Reports Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1868279/000110465926024112/avbp-20260305xex99d1.htm)) |
| March 5, 2026 | [Kura Oncology, Inc. earnings report](https://sec-api.dev/companies/kura/catalysts) | KURA |  | completed | "Kura Oncology Reports Fourth Quarter and full year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422143/000119312526092465/kura-ex99_1.htm)) |
| March 5, 2026 | [NextCure, Inc. earnings report](https://sec-api.dev/companies/nxtc/catalysts) | NXTC |  | completed | "Reports Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661059/000110465926024121/nxtc-20260305xex99d1.htm)) |
| March 5, 2026 | [REGENXBIO Inc. earnings report](https://sec-api.dev/companies/rgnx/catalysts) | RGNX |  | completed | "REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590877/000119312526092566/rgnx-ex99_1.htm)) |
| March 5, 2026 | [Phio Pharmaceuticals Corp. earnings report](https://sec-api.dev/companies/phio/catalysts) | PHIO |  | completed | "Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1533040/000143774926007071/ex_899185.htm)) |
| March 5, 2026 | [Contineum Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ctnm/catalysts) | CTNM |  | completed | "CONTINEUM THERAPEUTICS REPORTS FOURTH-QUARTER 2025 FINANCIAL RESULTS; AFFIRMS KEY CLINICAL DEVELOPMENT MILESTONES" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1855175/000162828026015159/a2026_marchx8kxex991.htm)) |
| March 5, 2026 | [Evommune, Inc. earnings report](https://sec-api.dev/companies/evmn/catalysts) | EVMN |  | completed | "Evommune Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2044725/000119312526093920/evmn-ex99_1.htm)) |
| March 5, 2026 | [Compass Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cmpx/catalysts) | CMPX |  | completed | "Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1738021/000117184326001336/exh_991.htm)) |
| March 5, 2026 | [CorMedix Inc. earnings report](https://sec-api.dev/companies/crmd/catalysts) | CRMD |  | completed | "Inc. Reports FOURTH Quarter AND FULL YEAR 2025 Financial Results and provides business update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1410098/000121390026023881/ea027968001ex99-1.htm)) |
| March 5, 2026 | [Silence Therapeutics plc earnings report](https://sec-api.dev/companies/sln/catalysts) | SLN |  | completed | "Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1479615/000119312526092578/sln-ex99_1.htm)) |
| March 5, 2026 | [Altimmune, Inc. earnings report](https://sec-api.dev/companies/alt/catalysts) | ALT |  | completed | "Altimmune Announces Fourth Quarter and Full-year 2025 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1326190/000132619026000013/alt-20260305xex99d1.htm)) |
| March 5, 2026 | [Atea Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/avir/catalysts) | AVIR |  | completed | "Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1593899/000119312526093961/d118938dex991.htm)) |
| March 5, 2026 | [BridgeBio Oncology Therapeutics, Inc. earnings report](https://sec-api.dev/companies/bbot/catalysts) | BBOT |  | completed | "BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1869105/000119312526093997/bbot-ex99_1.htm)) |
| March 5, 2026 | [Metagenomi Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mgx/catalysts) | MGX |  | completed | "Metagenomi Therapeutics Reports Business Updates and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1785279/000119312526093943/mgx-ex99_1.htm)) |
| March 5, 2026 | [Aligos Therapeutics, Inc. earnings report](https://sec-api.dev/companies/algs/catalysts) | ALGS |  | completed | "Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1799448/000117184326001340/exh_991.htm)) |
| March 5, 2026 | [Lineage Cell Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lctx/catalysts) | LCTX |  | completed | "LINEAGE CELL THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/876343/000119312526093948/lctx-ex99_1.htm)) |
| March 5, 2026 | [Shattuck Labs, Inc. earnings report](https://sec-api.dev/companies/sttk/catalysts) | STTK |  | completed | "Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1680367/000162828026014987/sttk_ye2025earningsrelease.htm)) |
| March 5, 2026 | [Liquidia Corp earnings report](https://sec-api.dev/companies/lqda/catalysts) | LQDA |  | completed | "Liquidia Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819576/000110465926023794/tm267579d3_ex99-1.htm)) |
| March 5, 2026 | [IGALMI® (dexmedetomidine) topline data readout](https://sec-api.dev/pdufa/dexmedetomidine) | BTAIQ | opioid withdrawal symptoms in adults with opioid use disorder undergoing a methadone taper | completed, positive | "On March 5, 2026, the Company announced positive topline results from the Columbia Phase 2 investigator-sponsored trial evaluating BXCL501 for the treatment of opioid withdrawal symptoms in adults with opioid use disorder undergoing a methadone taper." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1720893/000110465926095965/btai-20260630x10q.htm)) |
| March 5, 2026 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Carcinoma, Squamous Cell; Skin Neoplasms | withdrawn | "NCT06295809 (A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)): Overall Status TERMINATED; Phase PHASE2, PHASE3; Primary Completion 2026-03-05 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06295809)) |
| March 5, 2026 | [Tecvayli (teclistamab-cqyv) label expansion decision](https://sec-api.dev/pdufa/teclistamab-cqyv) | JNJ |  | completed, approved | "BLA761291 SUPPL-18 (Efficacy): submission_status AP, submission_status_date 20260305, review_priority PRIORITY; sponsor_name JANSSEN BIOTECH; product TECVAYLI (TECLISTAMAB-CQYV)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761291%22)) |
| March 6, 2026 | [Immuneering Corp earnings report](https://sec-api.dev/companies/imrx/catalysts) | IMRX |  | completed | "Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1790340/000179034026000040/imrx-20260306xexx991.htm)) |
| March 6, 2026 | [BRISTOL MYERS SQUIBB CO PDUFA date](https://sec-api.dev/companies/bmy/catalysts) | BMY |  | scheduled | "The FDA assigned PDUFA goal date of March 6, 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/14272/000001427226000004/bmy-20251231.htm)) |
| March 6, 2026 | [Azora Therapeutics, Inc. (DE) earnings report](https://sec-api.dev/companies/azr/catalysts) | AZR |  | completed | "Reports 2025 Fiscal Year Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1513525/000121390026024336/ea028028201ex99-1.htm)) |
| March 6, 2026 | [PMV Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/pmvp/catalysts) | PMVP |  | completed | "PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1699382/000119312526095094/pmvp-ex99_1.htm)) |
| March 6, 2026 | [Jade Biosciences, Inc. earnings report](https://sec-api.dev/companies/jbio/catalysts) | JBIO |  | completed | "Jade Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1798749/000119312526094967/d69373dex991.htm)) |
| March 6, 2026 | [Sotyktu (deucravacitinib) label expansion decision](https://sec-api.dev/pdufa/deucravacitinib) | BMY |  | completed, approved | "NDA214958 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20260306, review_priority STANDARD; sponsor_name BRISTOL; product SOTYKTU (DEUCRAVACITINIB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214958%22)) |
| March 6, 2026 | [Tozorakimab primary completion](https://sec-api.dev/pdufa/tozorakimab) | AZN | Chronic Obstructive Pulmonary Disease (COPD) | completed | "NCT06040086 (Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-03-06 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06040086)) |
| March 6, 2026 | [Skyrizi (risankizumab-rzaa) label expansion decision](https://sec-api.dev/pdufa/risankizumab-rzaa) | ABBV |  | completed, approved | "BLA761105 SUPPL-42 (Efficacy): submission_status AP, submission_status_date 20260306, review_priority STANDARD; sponsor_name ABBVIE INC; product SKYRIZI (RISANKIZUMAB-RZAA)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761105%22)) |
| March 6, 2026 | [Xeljanz (tofacitinib citrate) label expansion decision](https://sec-api.dev/pdufa/tofacitinib) | PFE |  | completed, approved | "NDA203214 SUPPL-41 (Efficacy): submission_status AP, submission_status_date 20260306, review_priority STANDARD; sponsor_name PF PRISM CV; product XELJANZ (TOFACITINIB CITRATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA203214%22)) |
| March 9, 2026 | [Dianthus Therapeutics, Inc. /DE/ earnings report](https://sec-api.dev/companies/dnth/catalysts) | DNTH |  | completed | "AND REPORTS Q4 AND FY 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1690585/000119312526097555/dnth-ex99_1.htm)) |
| March 9, 2026 | [Peptibody topline data readout](https://sec-api.dev/pdufa/peptibody) | NBP |  | completed, positive | "ROCKVILLE, MD, March 9, 2026 - NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovative medicines, and its subsidiary, Visara, Inc. (Visara), today announced positive topline results from the Phase 2a study of VIS-101, a purpose-designed tetravalent, dual VEGF-A X ANG-2 inhibitor in development for retinal vascular diseases including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1778016/000119312526097536/nbp-ex99_1.htm)) |
| March 9, 2026 | [Aldosterone NDA/BLA acceptance](https://sec-api.dev/pdufa/aldosterone) | MLYS |  | completed | "RADNOR, Pa., March 9, 2026 -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for lorundrostat for the treatment of adult patients with hypertension in combination with other antihypertensive drugs." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000048/mlys202603068kex991.htm)) |
| March 9, 2026 | [Coherus Oncology, Inc. earnings report](https://sec-api.dev/companies/chrs/catalysts) | CHRS |  | completed | "Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1512762/000110465926025293/chrs-20260309xex99d1.htm)) |
| March 9, 2026 | [MACROGENICS INC earnings report](https://sec-api.dev/companies/mgnx/catalysts) | MGNX |  | completed | "MacroGenics Reports 2025 Financial Results and Highlights Upcoming Planned Data Disclosures" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1125345/000112534526000018/exhibit99-1earningspressre.htm)) |
| March 9, 2026 | [Lorundrostat NDA/BLA acceptance](https://sec-api.dev/pdufa/lorundrostat) | MLYS | hypertension | completed | "On March 9, 2026, Mineralys Therapeutics, Inc. (the Company) issued a press release announcing U.S. Food and Drug Administration (FDA) acceptance of its New Drug Application (NDA) for lorundrostat for the treatment of adult patients with hypertension in combination with other antihypertensive drugs and topline results from the Company's Phase 2 Explore-OSA exploratory trial." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000048/mlys-20260306.htm)) |
| March 9, 2026 | [Septerna, Inc. earnings report](https://sec-api.dev/companies/sepn/catalysts) | SEPN |  | completed | "Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1984086/000119312526098489/sepn-ex99_1.htm)) |
| March 9, 2026 | [ARS Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/spry/catalysts) | SPRY |  | completed | "ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization neffy delivers $72.2 million of U.S. net product revenue in first full year" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671858/000119312526097467/spry-ex99_1.htm)) |
| March 9, 2026 | [Corbus Pharmaceuticals Holdings, Inc. earnings report](https://sec-api.dev/companies/crbp/catalysts) | CRBP |  | completed | "Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1595097/000119312526097582/crbp-ex99_1.htm)) |
| March 9, 2026 | [Azetukalner topline data readout](https://sec-api.dev/pdufa/azetukalner) | XENE |  | completed, positive | "On March 9, 2026, Xenon announced positive topline data from the Phase 3 X-TOLE2 study of azetukalner in FOS." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1582313/000119312526102517/d83218d424b5.htm)) |
| March 9, 2026 | [EnGene Therapeutics Inc. earnings report](https://sec-api.dev/companies/engn/catalysts) | ENGN |  | completed | "EX-99.1 enGene Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1980845/000119312526097534/engn-ex99_1.htm)) |
| March 9, 2026 | [Design Therapeutics, Inc. earnings report](https://sec-api.dev/companies/dsgn/catalysts) | DSGN |  | completed | "Design Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1807120/000119312526098474/dsgn-ex99_1.htm)) |
| March 9, 2026 | [CDI-988 trial start](https://sec-api.dev/pdufa/cdi-988) | COCP |  | completed | "announces the first subjects have been dosed in a Phase 1b norovirus challenge study (NCT07198139) to evaluate CDI-988 as both a preventive and treatment for norovirus infections." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1412486/000149315226009309/ex99-1.htm)) |
| March 9, 2026 | [SPRUCE BIOSCIENCES, INC. earnings report](https://sec-api.dev/companies/sprb/catalysts) | SPRB |  | completed | "Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1683553/000119312526097561/sprb-ex99_1.htm)) |
| March 9, 2026 | [Editas Medicine, Inc. earnings report](https://sec-api.dev/companies/edit/catalysts) | EDIT |  | completed | "CAMBRIDGE, Mass., March 9, 2026 - Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the fourth quarter and full year 2025 and provided business updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1650664/000165066426000013/editasmedicinepressrelease.htm)) |
| March 9, 2026 | [Cartesian Therapeutics, Inc. earnings report](https://sec-api.dev/companies/rnac/catalysts) | RNAC |  | completed | "Cartesian Therapeutics Reports Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1453687/000145368726000063/exhibit991_earningsrelease.htm)) |
| March 9, 2026 | [Wellcovorin (leucovorin calcium) label expansion decision](https://sec-api.dev/pdufa/leucovorin) | GSK |  | completed, approved | "NDA018342 SUPPL-15 (Efficacy): submission_status AP, submission_status_date 20260309, review_priority PRIORITY; sponsor_name GLAXOSMITHKLINE; product WELLCOVORIN (LEUCOVORIN CALCIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA018342%22)) |
| March 9, 2026 | [Biib122 225 mg primary completion](https://sec-api.dev/pdufa/biib122) | BIIB | Parkinson Disease | completed | "NCT05348785 (A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson's Disease in Adults Between the Ages of 30 and 80): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-03-09 (ACTUAL); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05348785)) |
| March 9, 2026 | [Etavopivat primary completion](https://sec-api.dev/pdufa/etavopivat) | NVO | Sickle Cell Disease | completed | "NCT05725902 (Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-03-09 (ACTUAL); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05725902)) |
| March 10, 2026 | [ImageneBio, Inc. earnings report](https://sec-api.dev/companies/ima/catalysts) | IMA |  | completed | "ImageneBio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1835579/000119312526099422/d130344dex991.htm)) |
| March 10, 2026 | [Opus Genetics, Inc. earnings report](https://sec-api.dev/companies/ird/catalysts) | IRD |  | completed | "Opus Genetics Announces Financial Results for" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1228627/000114036126008621/ef20067388_ex99-1.htm)) |
| March 10, 2026 | [TENAX THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/tenx/catalysts) | TENX |  | completed | "Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/34956/000165495426002072/tennx_ex991.htm)) |
| March 10, 2026 | [SIGA TECHNOLOGIES INC earnings report](https://sec-api.dev/companies/siga/catalysts) | SIGA |  | completed | "SIGA Reports Financial Results for Three and Twelve" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1010086/000114036126008782/ef20067458_ex99-1.htm)) |
| March 10, 2026 | [Cullinan Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cgem/catalysts) | CGEM |  | completed | "Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1789972/000119312526099355/cgem-ex99_1.htm)) |
| March 10, 2026 | [VTv Therapeutics Inc. earnings report](https://sec-api.dev/companies/vtvt/catalysts) | VTVT |  | completed | "Exhibit 99.1 vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1641489/000164148926000011/vtvt-20251231xexx991pressr.htm)) |
| March 10, 2026 | [Skye Bioscience, Inc. earnings report](https://sec-api.dev/companies/skye/catalysts) | SKYE |  | completed | "Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1516551/000162828026016400/a260310_skyexye25financial.htm)) |
| March 10, 2026 | [Q32 Bio Inc. earnings report](https://sec-api.dev/companies/qttb/catalysts) | QTTB |  | completed | "Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1661998/000119312526099328/qttb-ex99_1.htm)) |
| March 10, 2026 | [Rapport Therapeutics, Inc. earnings report](https://sec-api.dev/companies/rapp/catalysts) | RAPP |  | completed | "Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2012593/000119312526099336/rapp-ex99_1.htm)) |
| March 10, 2026 | [Artiva Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/artv/catalysts) | ARTV |  | completed | "Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1817241/000119312526100131/artv-ex99_1.htm)) |
| March 10, 2026 | [Prelude Therapeutics Inc earnings report](https://sec-api.dev/companies/prld/catalysts) | PRLD |  | completed | "Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1678660/000119312526099424/prld-ex99_1.htm)) |
| March 10, 2026 | [Deramiocel PDUFA date](https://sec-api.dev/pdufa/deramiocel) | CAPR |  | completed, complete response letter | "Press Release, titled "Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA", dated March 10, 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1133869/000110465926025657/capr-20260310x8k.htm)) |
| March 10, 2026 | [LYMPHIR (lymphir) trial start](https://sec-api.dev/pdufa/lymphir) | CTOR |  | completed | "On March 10, 2026, we issued a press release announcing positive topline results from a completed investigator-initiated Phase 1 clinical trial conducted by University of Pittsburgh investigators." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1851484/000121390026025464/ea0280663-8k_citius.htm)) |
| March 10, 2026 | [Protara Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tara/catalysts) | TARA |  | completed | "Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1359931/000121390026025432/ea028040401ex99-1.htm)) |
| March 10, 2026 | [Citius Pharmaceuticals, Inc. topline data readout](https://sec-api.dev/companies/ctxr/catalysts) | CTXR |  | completed, positive | "On March 10, 2026, Citius Oncology announced positive topline results from a completed investigator-initiated Phase 1 clinical trial conducted by University of Pittsburgh investigators." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1506251/000121390026090185/ea0301919-10q_citius.htm)) |
| March 10, 2026 | [NATURES SUNSHINE PRODUCTS INC earnings report](https://sec-api.dev/companies/natr/catalysts) | NATR |  | completed | "Nature's Sunshine Reports Strong Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/275053/000162828026016535/natrq42025earningsrelease.htm)) |
| March 10, 2026 | [Deramiocel complete response letter (CRL)](https://sec-api.dev/pdufa/deramiocel) | CAPR | Duchenne muscular dystrophy | completed, complete response letter | "On March 10, 2026, Capricor Therapeutics, Inc. (the "Company" or "Caprcior") issued a press release announcing that the U.S. Food and Drug Administration ("FDA") has lifted the previously issued Complete Response Letter ("CRL") and resumed review of its Biologics License Application ("BLA") seeking full approval of Deramiocel, an investigational cell therapy, for the treatment of Duchenne muscular dystrophy ("DMD") cardiomyopathy." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1133869/000110465926025657/capr-20260310x8k.htm)) |
| March 10, 2026 | [Lipocine Inc. earnings report](https://sec-api.dev/companies/lpcn/catalysts) | LPCN |  | completed | "Announces Financial Results for the Full Year Ended December 31, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1535955/000149315226009428/ex99-1.htm)) |
| March 10, 2026 | [ADC Therapeutics SA earnings report](https://sec-api.dev/companies/adct/catalysts) | ADCT |  | completed | "ADC Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Operational Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1771910/000162828026016238/adctq425pressrelease.htm)) |
| March 10, 2026 | [CITIUS ONCOLOGY, INC. topline data readout](https://sec-api.dev/companies/ctor/catalysts) | CTOR |  | completed, positive | "On March 10, 2026, we announced positive topline results from a completed investigator-initiated Phase 1 clinical trial conducted by University of Pittsburgh investigators." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1851484/000121390026090184/ea0301678-10q_citius.htm)) |
| March 10, 2026 | [Nplate (romiplostim) primary completion](https://sec-api.dev/pdufa/romiplostim) | AMGN | Chemotherapy-induced Thrombocytopenia | completed | "NCT03937154 (Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-03-10 (ACTUAL); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03937154)) |
| March 10, 2026 | [Ml-004 (ir)/(er) tablet primary completion](https://sec-api.dev/pdufa/ml-004-ir-er) | MPLT | Autism Spectrum Disorder | completed | "NCT05081245 (ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-03-10 (ACTUAL); Lead Sponsor MapLight Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05081245)) |
| March 11, 2026 | [Tenaya Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tnya/catalysts) | TNYA |  | completed | "Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1858848/000119312526102170/tnya-ex99_1.htm)) |
| March 11, 2026 | [PLIANT THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/plrx/catalysts) | PLRX |  | completed | "Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1746473/000174647326000039/plrx-20260311xexx991.htm)) |
| March 11, 2026 | [SGT-003 interim data readout](https://sec-api.dev/pdufa/sgt-003) | SLDB | Duchenne muscular dystrophy | completed, positive | "On March 11, 2026, the Company announced positive new interim data from its Phase 1/2 INSPIRE DUCHENNE clinical trial, a Phase 1/2 first-in-human, open-label, single-dose, multicenter trial designed to evaluate the safety, tolerability and efficacy of SGT-003 in pediatric participants with Duchenne muscular dystrophy ("Duchenne") at a dose level of 1E14vg/kg." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1707502/000119312526102489/sldb-20260311.htm)) |
| March 11, 2026 | [Verrica Pharmaceuticals Inc. earnings report](https://sec-api.dev/companies/vrca/catalysts) | VRCA |  | completed | "Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1660334/000119312526101126/d94203dex991.htm)) |
| March 11, 2026 | [Evofem Biosciences, Inc. earnings report](https://sec-api.dev/companies/evfm/catalysts) | EVFM |  | completed | "DIEGO, CA, March 11, 2026 — Women's health innovator Evofem Biosciences, Inc. (Evofem or the Company) (OTCID: EVFM), today announced financial results for the fourth quarter and year ended December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1618835/000149315226009689/ex99-1.htm)) |
| March 11, 2026 | [Sagimet Biosciences Inc. earnings report](https://sec-api.dev/companies/sgmt/catalysts) | SGMT |  | completed | "Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1400118/000110465926026146/tm268496d1_ex99-1.htm)) |
| March 11, 2026 | [Minerva Neurosciences, Inc. earnings report](https://sec-api.dev/companies/nerv/catalysts) | NERV |  | completed | "Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1598646/000119312526101074/d825896dex991.htm)) |
| March 11, 2026 | [VYVGART (efgartigimod) primary completion](https://sec-api.dev/pdufa/efgartigimod) | ARGX | Primary Immune Thrombocytopenia | completed | "NCT04225156 (A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP).): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-03-11 (ACTUAL); Lead Sponsor argenx." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04225156)) |
| March 11, 2026 | [Diranersen primary completion](https://sec-api.dev/pdufa/diranersen) | BIIB | Mild Cognitive Impairment Due to Alzheimer's Disease; Alzheimer's Disease Dementia | completed | "NCT05399888 (A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-03-11 (ACTUAL); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05399888)) |
| March 12, 2026 | [Lyell Immunopharma, Inc. earnings report](https://sec-api.dev/companies/lyel/catalysts) | LYEL |  | completed | "Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1806952/000162828026017244/lyel-20260312x8kexx991.htm)) |
| March 12, 2026 | [Candel Therapeutics, Inc. earnings report](https://sec-api.dev/companies/cadl/catalysts) | CADL |  | completed | "Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1841387/000119312526103126/cadl-ex99_1.htm)) |
| March 12, 2026 | [GYRE THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/gyre/catalysts) | GYRE |  | completed | "Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1124105/000119312526102700/gyre-ex99_1.htm)) |
| March 12, 2026 | [Century Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ipsc/catalysts) | IPSC |  | completed | "March 12, 2026 -- Century Therapeutics, Inc. ('Century', NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer, today reported financial results for the full year ended December 31, 2025, and recent business highlights." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1850119/000110465926026761/tm268574d1_ex99-1.htm)) |
| March 12, 2026 | [Seres Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mcrb/catalysts) | MCRB |  | completed | "CAMBRIDGE, Mass.- March 12, 2026 - Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today reported fourth quarter and full year 2025 financial results and provided business updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1609809/000119312526103034/d98522dex991.htm)) |
| March 12, 2026 | [PRECISION BIOSCIENCES INC earnings report](https://sec-api.dev/companies/dtil/catalysts) | DTIL |  | completed | "Precision BioSciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1357874/000162828026017018/dtil-20260312ex991.htm)) |
| March 12, 2026 | [INOVIO PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/ino/catalysts) | INO |  | completed | "INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1055726/000105572626000009/ino-123125x8kex991.htm)) |
| March 12, 2026 | [Erasca, Inc. earnings report](https://sec-api.dev/companies/eras/catalysts) | ERAS |  | completed | "Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1761918/000119312526104105/eras-ex99_1.htm)) |
| March 12, 2026 | [Theriva Biologics, Inc. earnings report](https://sec-api.dev/companies/tovx/catalysts) | TOVX |  | completed | "Biologics Reports Full-Year 2025 Operational Highlights and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/894158/000110465926026765/tm268491d1_ex99-1.htm)) |
| March 12, 2026 | [Korro Bio, Inc. earnings report](https://sec-api.dev/companies/krro/catalysts) | KRRO |  | completed | "Korro Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1703647/000119312526104135/krro-ex99_1.htm)) |
| March 12, 2026 | [Whitehawk Therapeutics, Inc. earnings report](https://sec-api.dev/companies/whwk/catalysts) | WHWK |  | completed | "Whitehawk Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1422142/000119312526103117/whwk-ex99_1.htm)) |
| March 12, 2026 | [MBX Biosciences, Inc. earnings report](https://sec-api.dev/companies/mbx/catalysts) | MBX |  | completed | "MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1776111/000119312526103118/mbx-ex99_1.htm)) |
| March 12, 2026 | [Mineralys Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mlys/catalysts) | MLYS |  | completed | "Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000054/mlysfy258kex991.htm)) |
| March 12, 2026 | [FILANA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/flna/catalysts) | FLNA |  | completed | "Filana Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1069530/000117184326001506/exh_991.htm)) |
| March 12, 2026 | [Adicet Bio, Inc. earnings report](https://sec-api.dev/companies/acet/catalysts) | ACET |  | completed | "Adicet Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1720580/000172058026000006/acet-ex99_1.htm)) |
| March 12, 2026 | [CHAMPIONS ONCOLOGY, INC. earnings report](https://sec-api.dev/companies/csbr/catalysts) | CSBR |  | completed | "Hackensack, NJ - March 12, 2026 - Champions Oncology, Inc. (Nasdaq: CSBR), a leading translational oncology research organization, today announced its financial results for its third quarter of fiscal 2026, ended January 31, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/771856/000162828026017259/csbr8-k1312026exhibit991xq3.htm)) |
| March 12, 2026 | [Corvus Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/crvs/catalysts) | CRVS |  | completed | "Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1626971/000117184326001526/exh_991.htm)) |
| March 12, 2026 | [CAPRICOR THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/capr/catalysts) | CAPR |  | completed | "Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000110465926027037/capr-20260312xex99d1.htm)) |
| March 12, 2026 | [OnKure Therapeutics, Inc. earnings report](https://sec-api.dev/companies/okur/catalysts) | OKUR |  | completed | "OnKure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1637715/000119312526104104/okur-ex99_1.htm)) |
| March 12, 2026 | [Clene Inc. earnings report](https://sec-api.dev/companies/clnn/catalysts) | CLNN |  | completed | "CLENE REPORTS FULL YEAR 2025 FINANCIAL RESULTS" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1822791/000143774926007828/ex_874803.htm)) |
| March 12, 2026 | [Vaxart, Inc. earnings report](https://sec-api.dev/companies/vxrt/catalysts) | VXRT |  | completed | "Vaxart Provides Business Update and Reports Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/72444/000143774926007968/ex_931491.htm)) |
| March 12, 2026 | [Elicio Therapeutics, Inc. earnings report](https://sec-api.dev/companies/eltx/catalysts) | ELTX |  | completed | "Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1601485/000160148526000026/elicioq425prdraft_31226.htm)) |
| March 12, 2026 | [Tonix Pharmaceuticals Holding Corp. earnings report](https://sec-api.dev/companies/tnxp/catalysts) | TNXP |  | completed | "Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided an overview of recent operational highlights." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1430306/000199937126005742/ex99-01.htm)) |
| March 12, 2026 | [Cancer earnings report](https://sec-api.dev/pdufa/cancer) | ALLO |  | completed | "SOUTH SAN FRANCISCO, Calif., March 12, 2026 - Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today provided corporate updates and reported financial results for the quarter and full year ended December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1737287/000162828026017230/allo-20260312xexx9912025pr.htm)) |
| March 12, 2026 | [NEKTAR THERAPEUTICS earnings report](https://sec-api.dev/companies/nktr/catalysts) | NKTR |  | completed | "PRESS RELEASE TITLED "NEKTAR THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS."" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/906709/000121390026027026/ea028133401ex99-1.htm)) |
| March 12, 2026 | [Bolt Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/bolt/catalysts) | BOLT |  | completed | "Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1641281/000119312526104102/bolt-ex99_1.htm)) |
| March 12, 2026 | [ONP-002 trial start](https://sec-api.dev/pdufa/onp-002) | OGEN |  | scheduled | "March 12, 2026, the Company intends to issue a press release announcing today announced it has completed the first site initiation visit (SIV) for its Phase IIa clinical trial of ONP-002 in Australia." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1174940/000149315226009682/form8-k.htm)) |
| March 12, 2026 | [IN8BIO, INC. earnings report](https://sec-api.dev/companies/inab/catalysts) | INAB |  | completed | "IN8bio Reports Fourth Quarter and Full-Year 2025 Financial Results - Highlights Durable Survival Improvements in Glioblastoma, Advancing Pipeline and Strengthened Financial Position for 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1740279/000119312526104144/inab-ex99_1.htm)) |
| March 12, 2026 | [Fianlimab primary completion](https://sec-api.dev/pdufa/fianlimab) | REGN | Melanoma | completed | "NCT05352672 (Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-03-12 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05352672)) |
| March 12, 2026 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Solid Tumor; Cutaneous Squamous Cell Carcinoma; Endometrial Cancer | completed | "NCT06036836 (Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-03-12 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06036836)) |
| March 12, 2026 | [BHV-7000 primary completion](https://sec-api.dev/pdufa/bhv-7000) | BHVN | Generalized Epilepsy | withdrawn | "NCT06425159 (A Study to Determine if BHV-7000 is Effective and Safe in Adults With Idiopathic Generalized Epilepsy With Generalized Tonic-clonic Seizures): Overall Status TERMINATED; Phase PHASE2, PHASE3; Primary Completion 2026-03-12 (ACTUAL); Lead Sponsor Biohaven Therapeutics Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06425159)) |
| March 12, 2026 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Lung Cancer; Non-Small Cell Lung Cancer | completed | "NCT06698042 (A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-03-12 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06698042)) |
| March 12, 2026 | [Cosentyx (secukinumab) label expansion decision](https://sec-api.dev/pdufa/secukinumab) | NVS |  | completed, approved | "BLA125504 SUPPL-91 (Efficacy): submission_status AP, submission_status_date 20260312, review_priority STANDARD; sponsor_name NOVARTIS PHARMS CORP; product COSENTYX (SECUKINUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125504%22)) |
| March 13, 2026 | [MZE001 trial start](https://sec-api.dev/pdufa/mze001) | MAZE |  | completed | "On March 13, 2026, the Company received notification from Shionogi that the first patient has been dosed in the Phase 2 study of MZE001 for Pompe disease." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1842295/000119312526122778/maze-20251231.htm)) |
| March 13, 2026 | [Xenetic Biosciences, Inc. earnings report](https://sec-api.dev/companies/xbio/catalysts) | XBIO |  | completed | "Inc. Reports Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534525/000168316826001744/xenetic_ex9901.htm)) |
| March 13, 2026 | [BioAffinity Technologies, Inc. earnings report](https://sec-api.dev/companies/biaf/catalysts) | BIAF |  | completed | "ANTONIO, Texas - March 13, 2026 - bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, today reported financial results for the year ended December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1712762/000149315226009986/ex99-1.htm)) |
| March 16, 2026 | [Annovis Bio, Inc. earnings report](https://sec-api.dev/companies/anvs/catalysts) | ANVS |  | completed | "Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1477845/000110465926028574/tm268976d1_ex99.htm)) |
| March 16, 2026 | [Alto Neuroscience, Inc. earnings report](https://sec-api.dev/companies/anro/catalysts) | ANRO |  | completed | "Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1999480/000199948026000001/exhibit991-earningsrelease.htm)) |
| March 16, 2026 | [Perspective Therapeutics, Inc. earnings report](https://sec-api.dev/companies/catx/catalysts) | CATX |  | completed | "SEATTLE - March 16, 2026 - Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us," and "our") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today provided a business update and announced full year results for the year ended December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/728387/000072838726000003/catx-ex99_1.htm)) |
| March 16, 2026 | [Zenas BioPharma, Inc. earnings report](https://sec-api.dev/companies/zbio/catalysts) | ZBIO |  | completed | "Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1953926/000110465926027961/tm268878d1_ex99-1.htm)) |
| March 16, 2026 | [CytomX Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ctmx/catalysts) | CTMX |  | completed | "CytomX Therapeutics Announces 2025 Financial Results and Provides" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1501989/000119312526107152/ctmx-ex99_1.htm)) |
| March 16, 2026 | [CYPHERPUNK TECHNOLOGIES INC. earnings report](https://sec-api.dev/companies/cyph/catalysts) | CYPH |  | completed | "MA - March 16, 2026 - Cypherpunk Technologies Inc., (Nasdaq: CYPH) ("Cypherpunk"), today reported financial results for the year ended December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1509745/000110465926028558/tm268792d1_ex99-1.htm)) |
| March 16, 2026 | [Aleniglipron topline data readout](https://sec-api.dev/pdufa/aleniglipron) | GPCR |  | completed, positive | "Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced positive topline data from the ACCESS clinical program of aleniglipron for the treatment of people living with obesity and/or overweight with at least one weight related co-morbidity." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1888886/000110465926028023/tm268880d1_ex99-1.htm)) |
| March 16, 2026 | [Black Diamond Therapeutics, Inc. earnings report](https://sec-api.dev/companies/bdtx/catalysts) | BDTX |  | completed | "Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701541/000170154126000008/bdtx-exhibit991_q42025.htm)) |
| March 16, 2026 | [Zomedica Corp. earnings report](https://sec-api.dev/companies/zomdf/catalysts) | ZOMDF |  | completed | "ANN ARBOR, MI / ACCESSWIRE / March 16, 2026 / Zomedica Corp. (OTCQB: ZOMDF) ("Zomedica" or the "Company"), an animal health company offering point-of-care diagnostic and therapeutic products for equine and companion animals, today reported consolidated financial results for the fourth quarter and year ended December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1684144/000165495426002304/zom_ex991.htm)) |
| March 16, 2026 | [Reproxalap PDUFA date](https://sec-api.dev/pdufa/reproxalap) | ALDX |  | completed, complete response letter | "On December 15, 2025, Aldeyra announced that the FDA had requested submission of the clinical study report for the field trial, triggering an extension of the PDUFA date to March 16, 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1341235/000119312526109511/aldx-20260317.htm)) |
| March 16, 2026 | [Coya Therapeutics, Inc. earnings report](https://sec-api.dev/companies/coya/catalysts) | COYA |  | completed | "Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1835022/000119312526107276/coya-ex99_1.htm)) |
| March 16, 2026 | [FMXIN002 topline data readout](https://sec-api.dev/pdufa/ns002) | NSRX |  | completed, positive | "AVIV, Israel, March 16, 2026 — Nasus Pharma Ltd. (NYSE: NSRX) ("Nasus Pharma" or the "Company"), a clinical-stage pharmaceutical company focused on the development of innovative intranasal products, today announced positive top line results from its" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2029039/000149315226010189/ex99-1.htm)) |
| March 16, 2026 | [AGENUS INC earnings report](https://sec-api.dev/companies/agen/catalysts) | AGEN |  | completed | "LEXINGTON, Mass. — March 16, 2026 — Agenus Inc. (Nasdaq: AGEN) today reported financial results for the fourth quarter and full year ended December 31, 2025, highlighting progress for the botensilimab (BOT) plus balstilimab (BAL) immunotherapy program across patient access, clinical execution, and commercial readiness." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1098972/000119312526107288/agen-ex99_1.htm)) |
| March 16, 2026 | [Olema Oncology, Inc. earnings report](https://sec-api.dev/companies/olma/catalysts) | OLMA |  | completed | "SAN FRANCISCO, March 16, 2026 (Globe NewsWire) - Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today reported financial and operating results for the fourth quarter and full year ended December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1750284/000119312526107154/olma-ex99_1.htm)) |
| March 16, 2026 | [Aldeyra Therapeutics, Inc. PDUFA date](https://sec-api.dev/companies/aldx/catalysts) | ALDX |  | scheduled | "The extended PDUFA target action date is March 16, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1341235/000119312525319638/aldx-ex99_1.htm)) |
| March 16, 2026 | [Cue Biopharma, Inc. earnings report](https://sec-api.dev/companies/cue/catalysts) | CUE |  | completed | "Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1645460/000119312526108292/cue-ex99_1.htm)) |
| March 16, 2026 | [LIFECORE BIOMEDICAL, INC. \DE\ earnings report](https://sec-api.dev/companies/lfcr/catalysts) | LFCR |  | completed | "Lifecore Biomedical Reports Financial Results for the Fourth Quarter and Transition Period Ended December 31, 2025, and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1005286/000100528626000007/lfcr-ty25q4xex991earningsr.htm)) |
| March 16, 2026 | [Atara Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/atra/catalysts) | ATRA |  | completed | "Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1604464/000119312526108344/atra-ex99_1.htm)) |
| March 16, 2026 | [Rafael Holdings, Inc. earnings report](https://sec-api.dev/companies/rfl/catalysts) | RFL |  | completed | "- Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the second quarter fiscal year 2026 ended January 31," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1713863/000121390026028311/ea028158201ex99-1.htm)) |
| March 16, 2026 | [Aprea Therapeutics, Inc. earnings report](https://sec-api.dev/companies/apre/catalysts) | APRE |  | completed | "Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1781983/000110465926028046/apre-20260316xex99d1.htm)) |
| March 16, 2026 | [KYNTRA BIO, INC. earnings report](https://sec-api.dev/companies/kynb/catalysts) | KYNB |  | completed | "Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921299/000119312526108324/kynb-ex99_1.htm)) |
| March 2026 | [Truqap (capivasertib) primary completion](https://sec-api.dev/pdufa/capivasertib) | AZN | Triple Negative Breast Neoplasms | delayed | "NCT03997123 (Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-03-16 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03997123)) |
| March 16, 2026 | [Elebsiran primary completion](https://sec-api.dev/pdufa/elebsiran) | VIR | Hepatitis B, Chronic | completed | "NCT04856085 (Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-03-16 (ACTUAL); Lead Sponsor Vir Biotechnology, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04856085)) |
| March 16, 2026 | [Foundayo (orforglipron calcium) primary completion](https://sec-api.dev/pdufa/orforglipron) | LLY | Type 2 Diabetes; Obesity; Overweight or Obesity | completed | "NCT05803421 (A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-03-16 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05803421)) |
| March 16, 2026 | [Biktarvy (bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate) primary completion](https://sec-api.dev/pdufa/bictegravir-emtricitabine-tenofovir-alafenamide) | GILD | HIV-1-infection | withdrawn | "NCT06613685 (Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated): Overall Status TERMINATED; Phase PHASE2, PHASE3; Primary Completion 2026-03-16 (ACTUAL); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06613685)) |
| March 16, 2026 | [Reproxalap complete response letter (CRL)](https://sec-api.dev/pdufa/reproxalap) | ALDX | dry eye disease | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA216442_20260316.pdf%22)) |
| March 17, 2026 | [CervoMed Inc. earnings report](https://sec-api.dev/companies/crvo/catalysts) | CRVO |  | completed | "CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1053691/000143774926008611/ex_933983.htm)) |
| March 17, 2026 | [Kalaris Therapeutics, Inc. earnings report](https://sec-api.dev/companies/klrs/catalysts) | KLRS |  | completed | "Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1754068/000119312526109437/d124100dex991.htm)) |
| March 17, 2026 | [Gossamer Bio, Inc. earnings report](https://sec-api.dev/companies/goss/catalysts) | GOSS |  | completed | "Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1728117/000172811726000018/goss-20260317xexx991.htm)) |
| March 17, 2026 | [BICYCLE THERAPEUTICS PLC earnings report](https://sec-api.dev/companies/bcyc/catalysts) | BCYC |  | completed | "technology, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided recent corporate updates." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1761612/000110465926028954/tm268887d1_ex99-1.htm)) |
| March 17, 2026 | [ABEONA THERAPEUTICS INC. earnings report](https://sec-api.dev/companies/abeo/catalysts) | ABEO |  | completed | "Therapeutics® Reports Full Year 2025 Financial Results and Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/318306/000149315226010408/ex99-1.htm)) |
| March 17, 2026 | [AN2 Therapeutics, Inc. earnings report](https://sec-api.dev/companies/antx/catalysts) | ANTX |  | completed | "AN2 Therapeutics Reports Fourth Quarter and Full Year End 2025 Financial Results and Recent Business and Scientific Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1880438/000119312526110681/antx-ex99_1.htm)) |
| March 17, 2026 | [Trevi Therapeutics, Inc. earnings report](https://sec-api.dev/companies/trvi/catalysts) | TRVI |  | completed | "Trevi Therapeutics Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1563880/000119312526110767/trvi-ex99_1.htm)) |
| March 17, 2026 | [Vireo Growth Inc. earnings report](https://sec-api.dev/companies/vreof/catalysts) | VREOF |  | completed | "Vireo Growth Inc. Announces Fourth Quarter 2025 Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1771706/000110465926028946/vreof-20260317xex99d1.htm)) |
| March 17, 2026 | [OV4071 earnings report](https://sec-api.dev/pdufa/ov4071) | OVID |  | completed | "Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1636651/000162828026019045/ovidexhibit9912025_x10-k.htm)) |
| March 17, 2026 | [SKYTROFA (lonapegsomatropin) topline data readout](https://sec-api.dev/pdufa/lonapegsomatropin) | ASND |  | completed, positive | "On March 17, 2026, the Company announced positive Week 52 topline results from New InsiGHTS, its Phase 2 randomized, open-label, active-controlled trial in the U.S. investigating the safety, tolerability, and efficacy of once-weekly TransCon hGH (lonapegsomatropin; U.S. FDA-approved for pediatric and adult growth hormone deficiency (GHD)" ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1612042/000119312526110751/d95087d6k.htm)) |
| March 17, 2026 | [Monte Rosa Therapeutics, Inc. earnings report](https://sec-api.dev/companies/glue/catalysts) | GLUE |  | completed | "Monte Rosa Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1826457/000119312526109353/glue-ex99_1.htm)) |
| March 17, 2026 | [ICOTYDE (icotrokinra) FDA approval](https://sec-api.dev/pdufa/icotrokinra) | JNJ |  | completed, approved | "Icotyde \| icotrokinra \| 3/17/2026 \| To treat moderate-to-severe plaque psoriasis in patients 12 years and older who weigh at least 40 kg and who are candidates for systemic therapy or phototherapy Drug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| March 17, 2026 | [Tebapivat primary completion](https://sec-api.dev/pdufa/tebapivat) | AGIO | Myelodysplastic Syndromes | completed | "NCT05490446 (A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-03-17 (ACTUAL); Lead Sponsor Agios Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05490446)) |
| March 17, 2026 | [Povofortay (povorcitinib) primary completion](https://sec-api.dev/pdufa/povorcitinib) | INCY | NonSegmental Vitiligo | completed | "NCT06113471 (A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-03-17 (ACTUAL); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06113471)) |
| March 17, 2026 | [Barzolvolimab primary completion](https://sec-api.dev/pdufa/barzolvolimab) | CLDX | Prurigo Nodularis | completed | "NCT06366750 (A Study of Barzolvolimab in Patients With Prurigo Nodularis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-03-17 (ACTUAL); Lead Sponsor Celldex Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06366750)) |
| March 18, 2026 | [Dogwood Therapeutics, Inc. earnings report](https://sec-api.dev/companies/dwtx/catalysts) | DWTX |  | completed | "ATLANTA, Ga., March 18, 2026 -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and neuropathy, today announced financial results for the fourth quarter and full year ended December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1818844/000110465926029992/dwtx-20260318xex99d1.htm)) |
| March 18, 2026 | [4D Molecular Therapeutics, Inc. earnings report](https://sec-api.dev/companies/fdmt/catalysts) | FDMT |  | completed | "4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1650648/000119312526113949/fdmt-ex99_1.htm)) |
| March 18, 2026 | [Protalix BioTherapeutics, Inc. earnings report](https://sec-api.dev/companies/plx/catalysts) | PLX |  | completed | "CARMIEL, Israel, March 18, 2026 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the discovery, development, production and commercialization of innovative therapeutics for rare diseases with significant unmet needs, today reported financial results for the fiscal year ended December 31, 2025, and provided a business and clinical update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1006281/000110465926029846/plx-20260318xex99d1.htm)) |
| March 18, 2026 | [PROKIDNEY CORP. earnings report](https://sec-api.dev/companies/prok/catalysts) | PROK |  | completed | "ProKidney Reports Full Year 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1850270/000119312526113893/prok-ex99_1.htm)) |
| March 18, 2026 | [Marker Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mrkr/catalysts) | MRKR |  | completed | "Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1094038/000110465926031309/tm268941d1_ex99-1.htm)) |
| March 18, 2026 | [Cingulate Inc. earnings report](https://sec-api.dev/companies/cing/catalysts) | CING |  | completed | "Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1862150/000149315226010881/ex99-1.htm)) |
| March 18, 2026 | [BHV-7000 primary completion](https://sec-api.dev/pdufa/bhv-7000) | BHVN | Major Depressive Disorder | completed | "NCT06423781 (Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-03-18 (ACTUAL); Lead Sponsor Biohaven Therapeutics Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06423781)) |
| March 19, 2026 | [SELLAS Life Sciences Group, Inc. earnings report](https://sec-api.dev/companies/sls/catalysts) | SLS |  | completed | "SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1390478/000139047826000004/sls-202603198xkexhibit991.htm)) |
| March 19, 2026 | [Inhibrx Biosciences, Inc. earnings report](https://sec-api.dev/companies/inbx/catalysts) | INBX |  | completed | "Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2007919/000200791926000007/exhibit99112312025.htm)) |
| March 19, 2026 | [RELMADA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/rlmd/catalysts) | RLMD |  | completed | "Relmada Therapeutics, Inc. (Nasdaq: RLMD, "Relmada" or the "Company"), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today reported audited financial results for the fourth quarter and full year ended December 31, 2025 and provided a corporate update highlighting significant progress across its pipeline." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1553643/000121390026032403/ea028268801ex99-1.htm)) |
| March 19, 2026 | [Emavusertib earnings report](https://sec-api.dev/pdufa/emavusertib) | CRIS |  | completed | "LEXINGTON, Mass., March 19, 2026 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today reported its business update and financial results for the quarter ended December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1108205/000110820526000030/a4q25earningspressrelease.htm)) |
| March 19, 2026 | [Acrivon Therapeutics, Inc. earnings report](https://sec-api.dev/companies/acrv/catalysts) | ACRV |  | completed | "Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1781174/000119312526115139/acrv-ex99_1.htm)) |
| March 19, 2026 | [Zura Bio Ltd earnings report](https://sec-api.dev/companies/zura/catalysts) | ZURA |  | completed | "Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1855644/000110465926032077/tm269296d1_ex99-1.htm)) |
| March 19, 2026 | [Eton Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/eton/catalysts) | ETON |  | completed | "Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1710340/000143774926009060/ex_889836.htm)) |
| March 19, 2026 | [Annamycin trial start](https://sec-api.dev/pdufa/annamycin) | MBRX |  | completed | "Announced a targeted new investigator-initiated Phase 1B/2 study of Annamycin in third-line pancreatic cancer with Atlantic Health, based on preclinical data suggesting activity in advanced pancreatic tumors." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1659617/000143774926008949/ex_934336.htm)) |
| March 19, 2026 | [Wegovy (semaglutide) FDA approval](https://sec-api.dev/pdufa/semaglutide) | NVO |  | completed, approved | "Bagsv&aelig;rd, Denmark, 19 March 2026 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Wegovy® HD (once-weekly injectable semaglutide 7.2 mg) to reduce excess body weight and maintain weight reduction long-term." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/353278/000117184326001813/f6k_031926.htm)) |
| March 19, 2026 | [Larimar Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lrmr/catalysts) | LRMR |  | completed | "Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374690/000119312526115119/lrmr-ex99_1.htm)) |
| March 19, 2026 | [Biofrontera Inc. earnings report](https://sec-api.dev/companies/bfri/catalysts) | BFRI |  | completed | "Inc. Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1858685/000149315226011545/ex99-1.htm)) |
| March 19, 2026 | [Mereo BioPharma Group plc earnings report](https://sec-api.dev/companies/mreo/catalysts) | MREO |  | completed | "Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1719714/000119312526115211/mreo-ex99_1.htm)) |
| March 19, 2026 | [IMCIVREE® (setmelanotide) FDA approval](https://sec-api.dev/pdufa/setmelanotide) | RYTM | acquired HO | completed, approved | "•On March 19, 2026, the Company announced IMCIVREE was approved by the FDA for the treatment of acquired HO;" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000162828026030136/q12026earningspr_draft.htm)) |
| March 19, 2026 | [ASSEMBLY BIOSCIENCES, INC. earnings report](https://sec-api.dev/companies/asmb/catalysts) | ASMB |  | completed | "Assembly Biosciences Reports Year-End 2025 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1426800/000119312526115980/asmb-ex99_1.htm)) |
| March 19, 2026 | [Moleculin Biotech, Inc. earnings report](https://sec-api.dev/companies/mbrx/catalysts) | MBRX |  | completed | "Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1659617/000143774926008949/ex_934336.htm)) |
| March 19, 2026 | [Taysha Gene Therapies, Inc. earnings report](https://sec-api.dev/companies/tsha/catalysts) | TSHA |  | completed | "Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1806310/000119312526115177/d46409dex991.htm)) |
| March 19, 2026 | [Eledon Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/eldn/catalysts) | ELDN |  | completed | "Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Operating and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1404281/000119312526116154/eldn-ex99_1.htm)) |
| March 19, 2026 | [ALUMIS INC. earnings report](https://sec-api.dev/companies/alms/catalysts) | ALMS |  | completed | "Alumis Reports Year End 2025 Financial Results and Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1847367/000184736726000004/alms-20260319xex99d1.htm)) |
| March 19, 2026 | [Pelthos Therapeutics Inc. earnings report](https://sec-api.dev/companies/pths/catalysts) | PTHS |  | completed | "Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1919246/000191924626000014/pths-pressreleasex20250319.htm)) |
| March 19, 2026 | [Iptacopan (part 1) primary completion](https://sec-api.dev/pdufa/iptacopan-part-1) | NVS | Lupus Nephritis | withdrawn | "NCT05268289 (Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-03-19 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05268289)) |
| March 19, 2026 | [Mazdutide primary completion](https://sec-api.dev/pdufa/mazdutide) | LLY | Alcohol Use Disorder | completed | "NCT06817356 (A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-03-19 (ACTUAL); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06817356)) |
| March 19, 2026 | [Wegovy (semaglutide) label expansion decision](https://sec-api.dev/pdufa/semaglutide) | NVO |  | completed, approved | "NDA215256 SUPPL-29 (Efficacy): submission_status AP, submission_status_date 20260319, review_priority STANDARD; sponsor_name NOVO; product WEGOVY (SEMAGLUTIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215256%22)) |
| March 19, 2026 | [IMCIVREE® (setmelanotide) label expansion decision](https://sec-api.dev/pdufa/setmelanotide) | RYTM | living with acquired hypothalamic obesity | completed, approved | "On March 19, 2026, Rhythm Pharmaceuticals, Inc. ("Rhythm") issued a press release and published a presentation announcing that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for IMCIVREE® (setmelanotide) to treat patients living with acquired hypothalamic obesity (HO), which is summarized under Item 8.01 below." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1649904/000162828026019995/rytm-20260319.htm)) |
| March 20, 2026 | [RM-718 PDUFA date](https://sec-api.dev/pdufa/rm-718) | RYTM |  | scheduled | "Next-generation assets *Pending FDA approval; the FDA's assigned PDUFA goal date is March 20, 2026; **pending regulatory feedback" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000162828026018211/ex992rytm20260313emanate.htm)) |
| March 20, 2026 | [IMCIVREE® (setmelanotide) PDUFA date](https://sec-api.dev/pdufa/setmelanotide) | RYTM | acquired hypothalamic obesity | completed, approved | "-- March 20, 2026 PDUFA goal date for sNDA for setmelanotide in acquired hypothalamic obesity --" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649904/000110465926021801/tm267699d1_ex99-1.htm)) |
| March 20, 2026 | [CARDAMYST (etripamil) earnings report](https://sec-api.dev/pdufa/etripamil) | MIST |  | completed | "Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1408443/000110465926032427/tm269403d1_ex99-1.htm)) |
| March 20, 2026 | [Tisotumab vedotin primary completion](https://sec-api.dev/pdufa/tisotumab-vedotin) | PFE | Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Exocrine Pancreatic Cancer | completed | "NCT03485209 (Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-03-20 (ACTUAL); Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03485209)) |
| March 20, 2026 | [Opdivo® (nivolumab) label expansion decision](https://sec-api.dev/pdufa/nivolumab) | BMY |  | completed, approved | "BLA125554 SUPPL-135 (Efficacy): submission_status AP, submission_status_date 20260320, review_priority PRIORITY; sponsor_name BRISTOL MYERS SQUIBB; product OPDIVO (NIVOLUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125554%22)) |
| March 23, 2026 | [Cabaletta Bio, Inc. earnings report](https://sec-api.dev/companies/caba/catalysts) | CABA |  | completed | "Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1759138/000175913826000010/caba-ex99_1.htm)) |
| March 23, 2026 | [TALPHERA, INC. earnings report](https://sec-api.dev/companies/tlph/catalysts) | TLPH |  | completed | "Talphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1427925/000143774926009299/ex_935735.htm)) |
| March 23, 2026 | [HMPL-760 trial start](https://sec-api.dev/pdufa/hmpl-760) | HCM | relapsed/refractory diffuse large B-cell lymphoma | completed | "Hong Kong, Shanghai & Florham Park, NJ — Monday, March 23, 2026: HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a registrational Phase III clinical trial of HMPL-760 in combination with R-GemOx (rituximab, gemcitabine and oxaliplatin) in patients with relapsed/refractory diffuse large B-cell lymphoma ("DLBCL") in China." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1648257/000164825726000021/hcm-20260323xex99d1.htm)) |
| March 23, 2026 | [Tab-cel (tabelecleucel) FDA approval](https://sec-api.dev/pdufa/tabelecleucel) | ATRA |  | completed, approved | "For example, on March 23, 2026, a putative securities class action captioned Kuang v. Atara Biotherapeutics, Inc., et al. was filed against us and certain of our current and former officers asserting claims based on alleged misstatements and omissions relating to manufacturing issues, the Phase 3 ALLELE study of tab-cel, and the likelihood of FDA approval of the tab-cel BLA." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1604464/000110465926125192/tmb-20260930x10q.htm)) |
| March 23, 2026 | [Xilio Therapeutics, Inc. earnings report](https://sec-api.dev/companies/xlo/catalysts) | XLO |  | completed | "Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1840233/000119312526118544/xlo-ex99_1.htm)) |
| March 23, 2026 | [Surrozen, Inc./DE earnings report](https://sec-api.dev/companies/srzn/catalysts) | SRZN |  | completed | "Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1824893/000119312526119757/srzn-ex99_1.htm)) |
| March 23, 2026 | [Pyxis Oncology, Inc. earnings report](https://sec-api.dev/companies/pyxs/catalysts) | PYXS |  | completed | "Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1782223/000119312526118525/pyxs-ex99_1.htm)) |
| March 23, 2026 | [Arbutus Biopharma Corp earnings report](https://sec-api.dev/companies/abus/catalysts) | ABUS |  | completed | "Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1447028/000117184326001838/exh_991.htm)) |
| March 23, 2026 | [Avalo Therapeutics, Inc. earnings report](https://sec-api.dev/companies/avtx/catalysts) | AVTX |  | completed | "Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1534120/000153412026000010/ex-991fy2025earningsrelease.htm)) |
| March 23, 2026 | [Aardvark Therapeutics, Inc. earnings report](https://sec-api.dev/companies/aard/catalysts) | AARD |  | completed | "Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1774857/000119312526119727/ck0001774857-ex99_1.htm)) |
| March 23, 2026 | [Azithromycin topline data readout](https://sec-api.dev/pdufa/azithromycin) | INSM |  | completed, positive | "BRIDGEWATER, N.J., Mar. 23, 2026 -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced positive topline results from the Phase 3b ENCORE study." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1104506/000114036126010651/ef20068516_ex99-1.htm)) |
| March 23, 2026 | [SUTRO BIOPHARMA, INC. earnings report](https://sec-api.dev/companies/stro/catalysts) | STRO |  | completed | "Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1382101/000119312526119844/stro-ex99_1.htm)) |
| March 24, 2026 | [COMPASS Pathways plc earnings report](https://sec-api.dev/companies/cmps/catalysts) | CMPS |  | completed | "Compass Pathways Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1816590/000181659026000021/q42025pressrelease.htm)) |
| March 24, 2026 | [Maze Therapeutics, Inc. earnings report](https://sec-api.dev/companies/maze/catalysts) | MAZE |  | completed | "Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1842295/000119312526122774/maze-ex99_1.htm)) |
| March 24, 2026 | [FENNEC PHARMACEUTICALS INC. earnings report](https://sec-api.dev/companies/fenc/catalysts) | FENC |  | completed | "FENNEC PHARMACEUTICALS REPORTS FOURTH Quarter AND FULL YEAR 2025 FINANCIAL RESULTS and provides business update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1211583/000110465926033885/fencf-20260324xex99d1.htm)) |
| March 24, 2026 | [Absci Corp earnings report](https://sec-api.dev/companies/absi/catalysts) | ABSI |  | completed | "VANCOUVER, Wash. and NEW YORK, March 24, 2026 - Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today reported financial and operating results for the quarter and full year ended December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1672688/000167268826000066/exhibit991-2025q410xkpr.htm)) |
| March 24, 2026 | [BioCardia, Inc. earnings report](https://sec-api.dev/companies/bcda/catalysts) | BCDA |  | completed | "BioCardia Reports 2025 Business Highlights and Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/925741/000143774926009609/ex_936455.htm)) |
| March 24, 2026 | [Linerixibat PDUFA date](https://sec-api.dev/pdufa/linerixibat) | GSK |  | scheduled | "Under the terms of the agreement, GSK will receive an upfront payment of $300 million, plus $100 million upon US FDA approval (expected prior to transaction closing, based on current PDUFA target approval date of 24 March 2026)." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1131399/000165495426002008/a8361v.htm)) |
| March 24, 2026 | [Neurogene earnings report](https://sec-api.dev/pdufa/neurogene) | NGNE |  | completed | "Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1404644/000140464426000012/ngne_4qye25earningsrelease.htm)) |
| March 24, 2026 | [BioAge Labs, Inc. earnings report](https://sec-api.dev/companies/bioa/catalysts) | BIOA |  | completed | "BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1709941/000119312526120864/bioa-ex99_1.htm)) |
| March 24, 2026 | [MAXCYTE, INC. earnings report](https://sec-api.dev/companies/mxct/catalysts) | MXCT |  | completed | "MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1287098/000110465926033867/mxct-20260324xex99d1.htm)) |
| March 24, 2026 | [Cisplatin trial start](https://sec-api.dev/pdufa/cisplatin) | FENC |  | completed | "STS-J01 in Japan: In December, Fennec announced positive topline results from the investigator-initiated Phase 2/3 STS-J01 clinical trial evaluating PEDMARK® for the reduction of cisplatin-induced ototoxicity in pediatric and adolescent and young adult (AYA) patients with non-metastatic solid tumors in Japan." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1211583/000110465926033885/fencf-20260324xex99d1.htm)) |
| March 24, 2026 | [LENZ Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lenz/catalysts) | LENZ |  | completed | "LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815776/000181577626000008/a991q425pressrelease.htm)) |
| March 24, 2026 | [Biomea Fusion, Inc. earnings report](https://sec-api.dev/companies/bmea/catalysts) | BMEA |  | completed | "Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1840439/000119312526121811/bmea-ex99_1.htm)) |
| March 24, 2026 | [MZE829 topline data readout](https://sec-api.dev/pdufa/mze829) | MAZE |  | completed, positive | "Today, Maze announced positive topline data from the Phase 2 HORIZON trial evaluating MZE829 in patients with broad AMKD." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1842295/000119312526122774/maze-ex99_1.htm)) |
| March 24, 2026 | [Avlayah (tividenofusp alfa-eknm) FDA approval](https://sec-api.dev/pdufa/tividenofusp-alfa-eknm) | DNLI |  | completed, approved | "Avlayah \| tividenofusp alfa-eknm \| 3/24/2026 \| To treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II)" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| March 25, 2026 | [Armata Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/armp/catalysts) | ARMP |  | completed | "Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/921114/000110465926034523/armp-20260325xex99d1.htm)) |
| March 25, 2026 | [EXICURE, INC. earnings report](https://sec-api.dev/companies/xcur/catalysts) | XCUR |  | completed | "Exicure, Inc. Reports Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1698530/000169853026000026/a8kye2025exhibit991.htm)) |
| March 25, 2026 | [BeyondSpring Inc. earnings report](https://sec-api.dev/companies/bysi/catalysts) | BYSI |  | completed | "BeyondSpring Reports 2025 Year-End Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1677940/000117184326001890/exh_991.htm)) |
| March 25, 2026 | [Journey Medical Corp earnings report](https://sec-api.dev/companies/derm/catalysts) | DERM |  | completed | "FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent corporate highlights for the full year ended December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1867066/000110465926034506/tm269707d1_ex99-1.htm)) |
| March 25, 2026 | [Entolimod (entolimod) earnings report](https://sec-api.dev/pdufa/entolimod) | VBIO |  | completed | "SAN ANTONIO, March 25, 2026 — Tivic Health Systems, Inc. (Nasdaq: TIVC), a development-stage immunotherapy company, today reported financial and operational results for the year ended December 31, 2025, and provided a business update highlighting the company's strategic transformation and focus on the development of its Entolimod™ platform." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787740/000143774926009789/ex_890784.htm)) |
| March 25, 2026 | [DYADIC INTERNATIONAL INC earnings report](https://sec-api.dev/companies/dyai/catalysts) | DYAI |  | completed | "DYAI), d/b/a, Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse commercial applications, today reported its financial results for 2025 along with significant corporate achievements." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1213809/000149315226012673/ex99-1.htm)) |
| March 25, 2026 | [Corcept FDA approval](https://sec-api.dev/pdufa/corcept) | CORT | with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer | completed, approved | "On March 25, 2026, Corcept Therapeutics Incorporated issued a press release announcing that the U.S. Food and Drug Administration has approved Lifyorli™ (relacorilant) in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1088856/000119312526123543/d123475d8k.htm)) |
| March 25, 2026 | [Tividenofusp alfa FDA approval](https://sec-api.dev/pdufa/tividenofusp-alfa) | DNLI | of neurologic manifestations in patients with Hunter syndrome | completed, approved | "On March 25, 2026, Denali Therapeutics Inc., a Delaware corporation (the "Company"), issued a press release announcing that the U.S. Food and Drug Administration approved AVLAYAHTM (tividenofusp alfa) for the treatment of of neurologic manifestations in patients with Hunter syndrome (MPS II) when initiated in presymptomatic or symptomatic pediatric patients weighing at least 5 kg prior to advanced neurologic impairment." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1714899/000171489926000030/dnli-20260325.htm)) |
| March 25, 2026 | [PRECIGEN, INC. earnings report](https://sec-api.dev/companies/pgen/catalysts) | PGEN |  | completed | "Precigen Reports Full Year 2025 Financial Results and Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1356090/000095010326004648/dp244075_ex9901.htm)) |
| March 25, 2026 | [Equillium, Inc. earnings report](https://sec-api.dev/companies/eq/catalysts) | EQ |  | completed | "Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1746466/000119312526124107/eq-ex99_1.htm)) |
| March 25, 2026 | [KIORA PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/kprx/catalysts) | KPRX |  | completed | "Encinitas, California — March 25, 2026 — Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a year-end business update on its pipeline of small molecules for the treatment of retinal diseases." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1372514/000137251426000025/ex991-pressreleasedecember.htm)) |
| March 25, 2026 | [MeiraGTx Holdings plc earnings report](https://sec-api.dev/companies/mgtx/catalysts) | MGTX |  | completed | "LONDON and NEW YORK, March 26, 2026 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced financial and operational results for the fourth quarter and full-year ended December 31, 2025, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1735438/000110465926034904/mgtx-20260325xex99d1.htm)) |
| March 25, 2026 | [Serina Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ser/catalysts) | SER |  | completed | "Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1708599/000170859926000018/ser-20260323xex991_earning.htm)) |
| March 25, 2026 | [ProMIS Neurosciences Inc. earnings report](https://sec-api.dev/companies/pmn/catalysts) | PMN |  | completed | "ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1374339/000110465926034162/pmn-20260325xex99d1.htm)) |
| March 25, 2026 | [Nkarta, Inc. earnings report](https://sec-api.dev/companies/nktx/catalysts) | NKTX |  | completed | "Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1787400/000178740026000005/nktx-ex99_1.htm)) |
| March 25, 2026 | [Alpha Cognition Inc. earnings report](https://sec-api.dev/companies/acog/catalysts) | ACOG |  | completed | "PRESS RELEASE ANNOUNCES FINANCIAL RESULTS FOR THE 2025 FISCAL YEAR DATED MARCH 26, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1655923/000121390026034778/ea028362201ex99-1.htm)) |
| March 25, 2026 | [TAXOL® (paclitaxel) FDA approval](https://sec-api.dev/pdufa/paclitaxel) | CORT | severe endocrinologic, oncologic, metabolic and neurologic disorders | completed, approved | "Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the U.S. Food and Drug Administration (FDA) has approved Lifyorli (relacorilant) in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1088856/000119312526123543/d123475dex991.htm)) |
| March 25, 2026 | [WAINUA (eplontersen) primary completion](https://sec-api.dev/pdufa/eplontersen) | IONS | Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM) | completed | "NCT04136171 (CARDIO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-03-25 (ACTUAL); Lead Sponsor Ionis Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04136171)) |
| March 25, 2026 | [Kesimpta (ofatumumab) primary completion](https://sec-api.dev/pdufa/ofatumumab) | NVS | Multiple Sclerosis (MS) | completed | "NCT04926818 (Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-03-25 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04926818)) |
| March 25, 2026 | [Xanomeline and trospium chloride capsules primary completion](https://sec-api.dev/pdufa/xanomeline-and-trospium) | BMY | Schizophrenia | completed | "NCT05304767 (An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-03-25 (ACTUAL); Lead Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05304767)) |
| March 25, 2026 | [Pelacarsen primary completion](https://sec-api.dev/pdufa/pelacarsen) | NVS | Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease | completed | "NCT06267560 (Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-03-25 (ACTUAL); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06267560)) |
| March 25, 2026 | [Orka-001 induction dose primary completion](https://sec-api.dev/pdufa/orka-001-induction-dose) | ORKA | Plaque Psoriasis | completed | "NCT07090330 (ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-03-25 (ACTUAL); Lead Sponsor Oruka Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07090330)) |
| March 26, 2026 | [Tarcocimab topline data readout](https://sec-api.dev/pdufa/tarcocimab) | KOD |  | completed, positive | "On March 26, 2026, Kodiak announced positive topline results in GLOW2, the second Phase 3 study of Zenkuda (tarcocimab tedromer) in diabetic retinopathy (DR), demonstrating superiority over sham." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1468748/000119312526211811/kod-ex99_1.htm)) |
| March 26, 2026 | [KRESLADI (marnetegragene autotemcel) FDA approval](https://sec-api.dev/pdufa/marnetegragene-autotemcel) | RCKT |  | completed, approved | "Rocket Pharmaceuticals Announces FDA Approval of" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1281895/000114036126011573/ef20069038_ex99-1.htm)) |
| March 26, 2026 | [TNX-1900 trial start](https://sec-api.dev/pdufa/tnx-1900) | TNXP |  | completed | "On March 26, 2026, the Company announced that the first participant was dosed in a Phase 1 investigator-initiated study to evaluate the effect of TNX-1900 on trigeminal nerve-mediated vasodilation of the forehead using capsaicin and electrical stimulation, a model for trigeminal neurovascular reactivity, in healthy female human volunteers." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1430306/000199937126006915/tnxp-8k_032526.htm)) |
| March 26, 2026 | [KAMADA LTD FDA approval](https://sec-api.dev/companies/kmda/catalysts) | KMDA |  | completed, approved | "26, 2026 -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that the U.S. Food and Drug Administration (FDA) has approved Kamada Plasma's collection center in San Antonio, TX." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1567529/000121390026034342/ea028343101ex99-1.htm)) |
| March 26, 2026 | [Kyverna Therapeutics, Inc. earnings report](https://sec-api.dev/companies/kytx/catalysts) | KYTX |  | completed | "Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1994702/000119312526126216/kytx-ex99_1.htm)) |
| March 26, 2026 | [Quoin Pharmaceuticals Ltd. earnings report](https://sec-api.dev/companies/qnrx/catalysts) | QNRX |  | completed | "Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671502/000110465926034951/tm269662d1_ex99-1.htm)) |
| March 26, 2026 | [Inhibikase Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ikt/catalysts) | IKT |  | completed | ""Company"), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hypertension ("PAH"), today reported financial results for the year ended" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1750149/000119312526126322/d119328dex991.htm)) |
| March 26, 2026 | [LeonaBio, Inc. earnings report](https://sec-api.dev/companies/lona/catalysts) | LONA |  | completed | "LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1620463/000119312526126579/lona-ex99_1.htm)) |
| March 26, 2026 | [Rani Therapeutics Holdings, Inc. earnings report](https://sec-api.dev/companies/rani/catalysts) | RANI |  | completed | "Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1856725/000119312526126240/rani-ex99_1.htm)) |
| March 26, 2026 | [Tedromer topline data readout](https://sec-api.dev/pdufa/tedromer) | KOD |  | completed, positive | "Palo Alto, CA — March 26, 2026 - Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced positive topline results in the GLOW2 Phase 3 superiority study of Zenkuda for the treatment of patients with diabetic retinopathy." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1468748/000119312526127041/d283186dex991.htm)) |
| March 26, 2026 | [Dermata Therapeutics, Inc. earnings report](https://sec-api.dev/companies/drma/catalysts) | DRMA |  | completed | "Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1853816/000149315226022710/ex99-1.htm)) |
| March 26, 2026 | [COGNITION THERAPEUTICS INC earnings report](https://sec-api.dev/companies/cgtx/catalysts) | CGTX |  | completed | "Reports Year End 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1455365/000110465926034876/tm269805d1_ex99-1.htm)) |
| March 26, 2026 | [Spero Therapeutics, Inc. earnings report](https://sec-api.dev/companies/spro/catalysts) | SPRO |  | completed | "Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1701108/000119312526126244/d107475dex991.htm)) |
| March 26, 2026 | [MetaVia Inc. earnings report](https://sec-api.dev/companies/mtva/catalysts) | MTVA |  | completed | "MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1638287/000110465926034907/mtva-20260326xex99d1.htm)) |
| March 26, 2026 | [Verekitug earnings report](https://sec-api.dev/pdufa/verekitug) | UPB |  | completed | "Upstream Bio Highlights Phase 3 Development Strategy for Verekitug and Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2022626/000119312526125057/upb-ex99_1.htm)) |
| March 26, 2026 | [Aptevo Therapeutics Inc. earnings report](https://sec-api.dev/companies/apvo/catalysts) | APVO |  | completed | "Aptevo Provides State of the Business Report and 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1671584/000119312526126190/apvo-ex99_1.htm)) |
| March 26, 2026 | [CV Sciences, Inc. earnings report](https://sec-api.dev/companies/cvsi/catalysts) | CVSI |  | completed | "CV Sciences, Inc. Reports Fiscal Year-End 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1510964/000119312526126211/cvsi-ex99_1.htm)) |
| March 26, 2026 | [Gain Therapeutics, Inc. earnings report](https://sec-api.dev/companies/ganx/catalysts) | GANX |  | completed | "Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1819411/000110465926035174/ganx-20260326xex99d1.htm)) |
| March 26, 2026 | [LB PHARMACEUTICALS INC earnings report](https://sec-api.dev/companies/lbrx/catalysts) | LBRX |  | completed | "LB Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1691082/000119312526126223/d129775dex991.htm)) |
| March 26, 2026 | [ROCKWELL MEDICAL, INC. earnings report](https://sec-api.dev/companies/rmti/catalysts) | RMTI |  | completed | "Wixom, Michigan, March 26, 2026 - Rockwell Medical, Inc. (the "Company") (Nasdaq: RMTI), a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products to dialysis providers worldwide, today announced financial and operational results for the three and twelve months ended December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1041024/000162828026021176/a2025q4fy-earningsxpr.htm)) |
| March 26, 2026 | [Zentalis Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/zntl/catalysts) | ZNTL |  | completed | "Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1725160/000172516026000010/zntl_q42025earningspr.htm)) |
| March 26, 2026 | [Acumen Pharmaceuticals, Inc. earnings report](https://sec-api.dev/companies/abos/catalysts) | ABOS |  | completed | "Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1576885/000162828026021189/abos-20260326xexx991.htm)) |
| March 26, 2026 | [DBV Technologies S.A. earnings report](https://sec-api.dev/companies/dbvt/catalysts) | DBVT |  | completed | "DBV Technologies Reports Full Year 2025 Financial Results and Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1613780/000119312526126671/d113165dex991.htm)) |
| March 26, 2026 | [Dare Bioscience, Inc. earnings report](https://sec-api.dev/companies/dare/catalysts) | DARE |  | completed | "Bioscience Reports Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401914/000149315226012902/ex99-1.htm)) |
| March 26, 2026 | [MapLight Therapeutics, Inc. earnings report](https://sec-api.dev/companies/mplt/catalysts) | MPLT |  | completed | "MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1770069/000119312526125062/mplt-ex99_1.htm)) |
| March 26, 2026 | [Awiqli Flextouch (insulin icodec) FDA approval](https://sec-api.dev/pdufa/insulin-icodec) | NVO |  | completed, approved | "BLA761326 ORIG-2 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20260326, review_priority STANDARD; sponsor_name NOVO NORDISK INC; product AWIQLI FLEXTOUCH (INSULIN ICODEC)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761326%22)) |
| March 26, 2026 | [JNJ-95475939 primary completion](https://sec-api.dev/pdufa/jnj-95475939) | JNJ | Dermatitis, Atopic | withdrawn | "NCT06881251 (A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-03-26 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06881251)) |
| March 27, 2026 | [IGALMI® (dexmedetomidine) earnings report](https://sec-api.dev/pdufa/dexmedetomidine) | BTAIQ |  | completed | "Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient Setting sNDA submitted seeking approval of IGALMI® in the at-home (outpatient) setting for the treatment of acute agitation associated with bipolar disorders or schizophrenia sNDA submission timeline supports potential approval as early as year-end 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1720893/000110465926035661/tm269970d1_ex99-1.htm)) |
| March 27, 2026 | [Calidi Biotherapeutics, Inc. earnings report](https://sec-api.dev/companies/cldi/catalysts) | CLDI |  | completed | "Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1855485/000149315226013236/ex99-1.htm)) |
| March 27, 2026 | [INTENSITY THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/ints/catalysts) | INTS |  | completed | "Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1567264/000156726426000025/ints20260327ex99120251231p.htm)) |
| March 27, 2026 | [Awiqli (awiqli) FDA approval](https://sec-api.dev/pdufa/awiqli) | NVO | type 2 diabetes | completed, approved | "Bagsv&aelig;rd, Denmark, 27 March 2026 - Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved Awiqli® (insulin icodec-abae) injection 700 units/mL, the first and only once-weekly, long-acting basal insulin, indicated as an adjunct to diet and exercise to improve glycaemic control (blood sugar) in adults living with type 2 diabetes." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/353278/000117184326001959/f6k_032626.htm)) |
| March 27, 2026 | [Monopar Therapeutics earnings report](https://sec-api.dev/companies/mnpr/catalysts) | MNPR |  | completed | "Wilmette, Ill., March 27, 2026 - Monopar Therapeutics Inc. ("Monopar," the "Company," "we") (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the fourth quarter and full-year 2025 financial results and provided a summary of recent developments." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1645469/000143774926010030/ex_937864.htm)) |
| March 27, 2026 | [Radiopharm Theranostics Ltd trial start](https://sec-api.dev/companies/radx/catalysts) | RADX |  | completed | "Sydney, Australia - 27 March 2026 - Radiopharm Theranostics (ASX:RAD, "Radiopharm" or the "Company"), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, today announced that the first patient has been dosed in its first-in-human" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1949257/000121390026035160/ea028376501_ex99-1.htm)) |
| March 27, 2026 | [AUCATZYL (obecabtagene autoleucel) earnings report](https://sec-api.dev/pdufa/obecabtagene-autoleucel) | AUTL |  | completed | "Autolus Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates March 27, 2026 at 7:00 AM EDT AUCATZYL® (obecabtagene autoleucel) net product revenue of $23.3 million* for the fourth quarter of 2025 and $74.3 million* for the full year of 2025 AUCATZYL® UK launch underway following successful National Institute for Health and Care Excellence (NICE) evaluation Autolus continues to expect full year 2026 AUCATZYL® net product revenue of $120 million to $135 million and shift to positive gross margin to occur in 2026 Independent real-world AUCATZYL® data from ROCCA consortium confirm high level of clinical activity with favorable safety profile Pivotal Phase 2 clinical trials with obe-cel in lupus nephritis and pediatric ALL enrolling" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1730463/000173046326000032/autlex-991pr270326.htm)) |
| March 27, 2026 | [Werewolf Therapeutics, Inc. earnings report](https://sec-api.dev/companies/howl/catalysts) | HOWL |  | completed | "Werewolf Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1785530/000178553026000005/a12312025ex991.htm)) |
| March 27, 2026 | [Entera Bio Ltd. earnings report](https://sec-api.dev/companies/entx/catalysts) | ENTX |  | completed | "Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1638097/000117891326001792/exhibit_99-1.htm)) |
| March 27, 2026 | [Enveric Biosciences, Inc. earnings report](https://sec-api.dev/companies/envb/catalysts) | ENVB |  | completed | "Biosciences Reports Financial Results and Provides Corporate Update for" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/890821/000149315226013290/ex99-1.htm)) |
| March 27, 2026 | [Degevma (denosumab-adet) FDA approval](https://sec-api.dev/pdufa/denosumab-adet) | TEVA |  | completed, approved | "BLA761385 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20260327, review_priority STANDARD; sponsor_name TEVA PHARMACEUTICALS, INC.; product PONLIMSI (DENOSUMAB-ADET)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761385%22)) |
| March 27, 2026 | [Alyftrek (deutivacaftor; tezacaftor; vanzacaftor calcium) label expansion decision](https://sec-api.dev/pdufa/deutivacaftor-tezacaftor-vanzacaftor) | VRTX |  | completed, approved | "NDA218730 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20260327, review_priority PRIORITY; sponsor_name VERTEX PHARMS INC; product ALYFTREK (DEUTIVACAFTOR; TEZACAFTOR; VANZACAFTOR CALCIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA218730%22)) |
| March 27, 2026 | [Senti Biosciences Holdings, Inc. earnings report](https://sec-api.dev/companies/snti/catalysts) | SNTI |  | completed | "Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1854270/000162828026021578/ex991sntiq425earningsrelea.htm)) |
| March 27, 2026 | [Trikafta (Copackaged) (elexacaftor, ivacaftor, tezacaftor; ivacaftor) label expansion decision](https://sec-api.dev/pdufa/elexacaftor-ivacaftor-tezacaftor-ivacaftor) | VRTX |  | completed, approved | "NDA217660 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20260327, review_priority PRIORITY; sponsor_name VERTEX PHARMS INC; product TRIKAFTA (COPACKAGED) (ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA217660%22)) |
| March 27, 2026 | [Epkinly (epcoritamab-bysp) label expansion decision](https://sec-api.dev/pdufa/epcoritamab-bysp) | GMAB |  | completed, approved | "BLA761324 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20260327, review_priority STANDARD; sponsor_name GENMAB US, INC.; product EPKINLY (EPCORITAMAB-BYSP)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761324%22)) |
| March 27, 2026 | [Instil Bio, Inc. earnings report](https://sec-api.dev/companies/til/catalysts) | TIL |  | completed | "Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1789769/000178976926000018/q4-2025earningspressrelease.htm)) |
| March 27, 2026 | [Disitamab vedotin primary completion](https://sec-api.dev/pdufa/disitamab-vedotin) | PFE | Carcinoma, Non-Small-Cell Lung; Ovarian Neoplasms; Endometrial Neoplasms | completed | "NCT06003231 (A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-03-27 (ACTUAL); Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06003231)) |
| March 27, 2026 | [REGN9933 primary completion](https://sec-api.dev/pdufa/regn9933) | REGN | Venous Thromboembolism | completed | "NCT06299111 (A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-03-27 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06299111)) |
| March 27, 2026 | [MRNA-1345 primary completion](https://sec-api.dev/pdufa/mrna-1345) | MRNA | Respiratory Syncytial Virus | completed | "NCT07117487 (A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-03-27 (ACTUAL); Lead Sponsor ModernaTX, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07117487)) |
| March 27, 2026 | [SPINRAZA (nusinersen) label expansion decision](https://sec-api.dev/pdufa/nusinersen) | BIIB |  | completed, approved | "NDA209531 SUPPL-16 (Efficacy): submission_status AP, submission_status_date 20260327, review_priority STANDARD; sponsor_name BIOGEN; product SPINRAZA (NUSINERSEN SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209531%22)) |
| March 28, 2026 | [KRESLADI (marnetegragene autotemcel) PDUFA date](https://sec-api.dev/pdufa/marnetegragene-autotemcel) | RCKT |  | completed, approved | "KRESLADI™ for severe LAD-I on track for March 28, 2026 PDUFA date" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1281895/000114036126006981/ef20066645_ex99-1.htm)) |
| March 28, 2026 | [ROCKET PHARMACEUTICALS, INC. PDUFA date](https://sec-api.dev/companies/rckt/catalysts) | RCKT |  | scheduled | "In October 2025, the FDA accepted the Company's resubmission of the BLA and assigned a PDUFA date of March 28, 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1281895/000119312526458320/rckt-20260930.htm)) |
| March 30, 2026 | [Aura Biosciences, Inc. earnings report](https://sec-api.dev/companies/aura/catalysts) | AURA |  | completed | "Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1501796/000119312526130383/aura-ex99_1.htm)) |
| March 30, 2026 | [Elegrobart topline data readout](https://sec-api.dev/pdufa/elegrobart) | VRDN |  | completed, positive | "WALTHAM, Mass. - March 30, 2026—Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today announced positive topline data from the elegrobart REVEAL-1 phase 3 clinical trial in patients with active thyroid eye disease (TED)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1590750/000119312526130433/d27955dex991.htm)) |
| March 30, 2026 | [AKY-2519 earnings report](https://sec-api.dev/pdufa/aky-2519) | AKTS |  | completed | "Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2035832/000119312526132524/ck0002035832-ex99_1.htm)) |
| March 30, 2026 | [Ribitol NDA/BLA submission](https://sec-api.dev/pdufa/ribitol) | BBIO |  | completed | "•On March 30, 2026, we submitted our NDA to the FDA for oral BBP-418 for the treatment of LGMD2I/R9." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1743881/000174388126000034/bbio-20260930.htm)) |
| March 30, 2026 | [Annexon, Inc. earnings report](https://sec-api.dev/companies/annx/catalysts) | ANNX |  | completed | "Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1528115/000119312526131746/annx-ex99_1.htm)) |
| March 30, 2026 | [Cancers earnings report](https://sec-api.dev/pdufa/cancers) | PDSB |  | completed | "PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1472091/000114036126011862/ef20069202_ex99-1.htm)) |
| March 30, 2026 | [TherapeuticsMD, Inc. earnings report](https://sec-api.dev/companies/txmd/catalysts) | TXMD |  | completed | "30, 2026 -- TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/25743/000121390026036519/ea028323901ex99-1.htm)) |
| March 30, 2026 | [Tempest Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tpst/catalysts) | TPST |  | completed | "Tempest Reports Year End 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1544227/000119312526130480/tpst-ex99_1.htm)) |
| March 30, 2026 | [DiaMedica Therapeutics Inc. earnings report](https://sec-api.dev/companies/dmac/catalysts) | DMAC |  | completed | "DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1401040/000143774926010409/ex_939162.htm)) |
| March 30, 2026 | [Faeth Therapeutics, Inc. earnings report](https://sec-api.dev/companies/fth/catalysts) | FTH |  | completed | "Sensei Biotherapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1829802/000119312526130419/d118677dex991.htm)) |
| March 30, 2026 | [Ensysce Biosciences, Inc. earnings report](https://sec-api.dev/companies/ensc/catalysts) | ENSC |  | completed | "Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1716947/000149315226013622/ex99-1.htm)) |
| March 30, 2026 | [SANGAMO THERAPEUTICS, INC earnings report](https://sec-api.dev/companies/sgmoq/catalysts) | SGMOQ |  | completed | "RICHMOND, California, March 30, 2026 - Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported recent business highlights and fourth quarter and full year 2025 financial results." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1001233/000162828026022006/exhibit-991033026.htm)) |
| March 30, 2026 | [Eikon Therapeutics, Inc. earnings report](https://sec-api.dev/companies/eikn/catalysts) | EIKN |  | completed | "Eikon Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Clinical and Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1861123/000119312526130449/d244624dex991.htm)) |
| March 30, 2026 | [Neumora Therapeutics, Inc. earnings report](https://sec-api.dev/companies/nmra/catalysts) | NMRA |  | completed | "Neumora Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1885522/000119312526130372/nmra-ex99_1.htm)) |
| March 30, 2026 | [Bicara Therapeutics Inc. earnings report](https://sec-api.dev/companies/bcax/catalysts) | BCAX |  | completed | "Bicara Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026021868/pressrelease-q42025.htm)) |
| March 30, 2026 | [Lantern Pharma Inc. earnings report](https://sec-api.dev/companies/ltrn/catalysts) | LTRN |  | completed | "RADR® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced operational highlights and financial results for the fourth quarter and full year 2025 ended" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1763950/000149315226013608/ex99-1.htm)) |
| March 30, 2026 | [Lexeo Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lxeo/catalysts) | LXEO |  | completed | "Lexeo Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1907108/000119312526131792/lxeo-ex99_1.htm)) |
| March 30, 2026 | [REVIVA PHARMACEUTICALS HOLDINGS, INC. earnings report](https://sec-api.dev/companies/rvph/catalysts) | RVPH |  | completed | "Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1742927/000143774926010140/ex_937921.htm)) |
| March 30, 2026 | [Veradermics, Inc earnings report](https://sec-api.dev/companies/mane/catalysts) | MANE |  | completed | "Veradermics Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Corporate and Clinical Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1827635/000182763526000010/exhibit9914qye2025earnings.htm)) |
| March 30, 2026 | [Unicycive Therapeutics, Inc. earnings report](https://sec-api.dev/companies/uncy/catalysts) | UNCY |  | completed | "Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1766140/000121390026035961/ea028394201ex99-1.htm)) |
| March 30, 2026 | [ABP-450 earnings report](https://sec-api.dev/pdufa/abp-450) | AEON |  | completed | "AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Program" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1837607/000183760726000018/aeon-20260330xex99d1.htm)) |
| March 30, 2026 | [Rademikibart topline data readout](https://sec-api.dev/pdufa/rademikibart) | CNTB | stable asthma or COPD | completed, positive | "SAN DIEGO, March 30, 2026, (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma, Connect or the Company), a clinical-stage biopharmaceutical company focused on transforming care for the treatment of inflammatory diseases, today reported positive topline preliminary results for its Phase 1 clinical pharmacology study evaluating intravenous (IV) rademikibart, the Company's next-generation, potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1835268/000183526826000006/exhibit991-phase1ivstudypr.htm)) |
| March 30, 2026 | [Epinephrine Bitartrate In 0.9% Sodium Chloride (epinephrine bitartrate) FDA approval](https://sec-api.dev/pdufa/epinephrine) | BAX |  | completed, approved | "NDA220626 ORIG-1 (New Combination and New Formulation or New Manufacturer): submission_status AP, submission_status_date 20260330, review_priority STANDARD; sponsor_name BAXTER HLTHCARE CORP; product EPINEPHRINE (EPINEPHRINE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA220626%22)) |
| March 30, 2026 | [Jasper Therapeutics, Inc. earnings report](https://sec-api.dev/companies/jspr/catalysts) | JSPR |  | completed | "Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1788028/000121390026036448/ea028336401ex99-1.htm)) |
| March 2026 | [Apl-101 oral capsules primary completion](https://sec-api.dev/pdufa/apl-101-oral) | APLM | Solid Tumors; Advanced Cancer; Renal Cancer | delayed | "NCT03175224 (APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-03-30 (ESTIMATED); Lead Sponsor Apollomics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03175224)) |
| March 30, 2026 | [MINJUVI (tafasitamab) primary completion](https://sec-api.dev/pdufa/tafasitamab) | INCY | Large B-Cell Lymphoma; Diffuse Large B-Cell Lymphoma | completed | "NCT05429268 (Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-03-30 (ACTUAL); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05429268)) |
| March 30, 2026 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Advanced Hepatocellular Carcinoma | completed | "NCT05883644 (Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-03-30 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05883644)) |
| March 30, 2026 | [NEREUSTM (tradipitant) primary completion](https://sec-api.dev/pdufa/tradipitant) | VNDA | Idiopathic Gastroparesis; Diabetic Gastroparesis; Gastroparesis | completed | "NCT06836557 (Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-03-30 (ACTUAL); Lead Sponsor Vanda Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06836557)) |
| March 30, 2026 | [Zynyz (retifanlimab-dlwr) label expansion decision](https://sec-api.dev/pdufa/retifanlimab-dlwr) | INCY |  | completed, approved | "BLA761334 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20260330, review_priority STANDARD; sponsor_name INCYTE CORP; product ZYNYZ (RETIFANLIMAB-DLWR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761334%22)) |
| March 31, 2026 | [Kodiak Sciences Inc. earnings report](https://sec-api.dev/companies/kod/catalysts) | KOD |  | completed | "Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1468748/000119312526134854/kod-ex99_1.htm)) |
| March 31, 2026 | [PALVELLA THERAPEUTICS, INC. earnings report](https://sec-api.dev/companies/pvla/catalysts) | PVLA |  | completed | "Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1583648/000119312526133332/pvla-ex99_1.htm)) |
| March 31, 2026 | [Stenoparib earnings report](https://sec-api.dev/pdufa/stenoparib) | ALLR |  | completed | "Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor—today announced financial results for the year ended December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1860657/000121390026038061/ea027957101ex99-1.htm)) |
| March 31, 2026 | [Lb-102 (50 mg tablet) trial start](https://sec-api.dev/pdufa/lb-102) | LBRX | bipolar 1 depression | completed | "During the three months ended March 31, 2026, the Company initiated a Phase 2 clinical trial (ILLUMINATE-1) of LB-102 in patients with bipolar 1 depression and a Phase 3 clinical trial (NOVA-2) of LB-102 in patients with acute schizophrenia." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1691082/000119312526219607/lbrx-20260331.htm)) |
| March 31, 2026 | [PT00114 trial start](https://sec-api.dev/pdufa/pt00114) | PTIX |  | scheduled | "Anticipate Q4 FY2026 (the quarter ending March 31, 2026) : Initiation of Phase IIa study for PT00114" ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1022899/000149315225025201/form10-q.htm)) |
| March 31, 2026 | [Turn Therapeutics Inc. earnings report](https://sec-api.dev/companies/ttrx/catalysts) | TTRX |  | completed | "Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted inflammatory and immunology therapies for dermatologic conditions, today reported financial results for the year ended December" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2023016/000121390026037470/ea028379501ex99-1.htm)) |
| March 31, 2026 | [Tvardi Therapeutics, Inc. earnings report](https://sec-api.dev/companies/tvrd/catalysts) | TVRD |  | completed | "31, 2026 - Tvardi Therapeutics, Inc. ("Tvardi") (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced its financial and operating results for the fourth quarter and full-year ended December 31, 2025, and provided a business update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1346830/000110465926037724/tm2610603d1_ex99-1.htm)) |
| March 31, 2026 | [MiNK Therapeutics, Inc. earnings report](https://sec-api.dev/companies/inkt/catalysts) | INKT |  | completed | "NEW YORK, NY — March 31, 2026 (Globe Newswire) — MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today reported financial results for the fourth quarter and full year ended December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1840229/000119312526133346/inkt-ex99_1.htm)) |
| March 31, 2026 | [Imunon, Inc. earnings report](https://sec-api.dev/companies/imnn/catalysts) | IMNN |  | completed | "Reports 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/749647/000149315226013816/ex99-1.htm)) |
| March 31, 2026 | [Connect Biopharma Holdings Ltd earnings report](https://sec-api.dev/companies/cntb/catalysts) | CNTB |  | completed | "Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1835268/000183526826000012/cntbpressreleaseyear-end20.htm)) |
| March 31, 2026 | [Spikevax (spikevax) FDA approval](https://sec-api.dev/pdufa/spikevax) | MRNA |  | completed, approved | "As of March 31, 2026, we have three commercial products, our COVID vaccines, Spikevax and mNEXSPIKE, and our RSV vaccine, mRESVIA. mRESVIA was approved by the FDA in May 2024 for adults aged 60 years and older, and in June 2025, the approved use was expanded to include adults aged 18 through 59 years who are at increased risk for lower respiratory tract disease caused by RSV." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1682852/000168285226000060/mrna-20260331.htm)) |
| March 31, 2026 | [Stenoparib trial start](https://sec-api.dev/pdufa/stenoparib) | ALLR |  | completed | "First Combination Trial Launched: During 2025, Allarity announced and initiated a Phase 2 trial evaluating stenoparib in combination with temozolomide for recurrent small cell lung cancer (SCLC), fully funded by the" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1860657/000121390026038061/ea027957101ex99-1.htm)) |
| March 31, 2026 | [Cocrystal Pharma, Inc. earnings report](https://sec-api.dev/companies/cocp/catalysts) | COCP |  | completed | "Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1412486/000149315226013837/ex99-1.htm)) |
| March 31, 2026 | [ISEMBYLD (apitegromab) NDA/BLA submission](https://sec-api.dev/pdufa/apitegromab) | SRRK | children and adults with SMA | completed | "On March 31, 2026, Scholar Rock Holding Corporation (the "Company") issued a press release announcing it resubmitted its biologics license application ("BLA") to the U.S. Food and Drug Administration (the "FDA") for apitegromab for the treatment of children and adults with spinal muscular atrophy ("SMA")." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1727196/000110465926037350/tm2610664d1_8k.htm)) |
| March 31, 2026 | [ORZEYFUL (oveporexton) NDA/BLA submission](https://sec-api.dev/pdufa/oveporexton) | TAK | excessive daytime sleepiness in NT1 | completed | "In the fiscal year ended March 31, 2026, we submitted New Drug Applications ("NDAs") in the U.S. for oveporexton and rusfertide following successful Phase 3 clinical trial results." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1395064/000139506426000177/tak-20260331.htm)) |
| March 31, 2026 | [OMEROS CORP earnings report](https://sec-api.dev/companies/omer/catalysts) | OMER |  | completed | "Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1285819/000143774926010634/ex_889301.htm)) |
| March 31, 2026 | [BioAtla, Inc. earnings report](https://sec-api.dev/companies/bcab/catalysts) | BCAB |  | completed | "BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and business Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1826892/000119312526134501/bcab-ex99_1.htm)) |
| March 31, 2026 | [Entyvio® (vedolizumab) NDA/BLA acceptance](https://sec-api.dev/pdufa/vedolizumab) | ALVO |  | completed | "Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1898416/000117184326003974/exh_991.htm)) |
| March 31, 2026 | [CAD-1005 earnings report](https://sec-api.dev/pdufa/cad-1005) | CVKD |  | completed | "Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, today reported its financial results for the fourth quarter and full year ended December 31, 2025, and provided a corporate update highlighting recent progress across its CAD-1005 program for HIT and broader 12-LOX inhibitor platform." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1937993/000121390026036937/ea028425801ex99-1.htm)) |
| March 31, 2026 | [ZYCUBO (CUTX-101) PDUFA date](https://sec-api.dev/pdufa/cutx-101) | FBIO |  | completed, approved | "As of December 31, 2025, although the NDA for CUTX-101 had been resubmitted and assigned a new PDUFA date of January 14, 2026, following the October 2024 Complete Response Letter, significant uncertainty remained regarding whether approval would be obtained, whether a PRV would be issued, and whether a PPS PRV Sale could be executed on a timely basis on agreeable terms prior to the March 31, 2026 mandatory exchange date." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1429260/000110465926126531/fbio-20260930x10q.htm)) |
| March 31, 2026 | [GALECTIN THERAPEUTICS INC earnings report](https://sec-api.dev/companies/galt/catalysts) | GALT |  | completed | "Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133416/000114036126012158/ef20068722_ex99-1.htm)) |
| March 31, 2026 | [Biologics earnings report](https://sec-api.dev/pdufa/biologics) | HCWB |  | completed | "Miramar, FL - March 31, 2026 - HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation, today reported financial results and recent business highlights for its three months ended December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1828673/000119312526134936/hcwb-ex99_1.htm)) |
| March 31, 2026 | [CUE-101 trial start](https://sec-api.dev/pdufa/cue-101) | CUE |  | completed | "As of March 31, 2026, two of these milestones had been achieved, as we had filed an IND application in 2019, and initiated an investigator sponsored Phase 1b neoadjuvant clinical trial for CUE-101 in locally advanced HNSCC in 2021." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1645460/000119312526224091/cue-20260331.htm)) |
| March 31, 2026 | [Fortress Biotech, Inc. earnings report](https://sec-api.dev/companies/fbio/catalysts) | FBIO |  | completed | "Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1429260/000110465926037749/fbio-20260331xex99.htm)) |
| March 31, 2026 | [HIBSAGO (bepirovirsen) trial start](https://sec-api.dev/pdufa/bepirovirsen) | IONS |  | completed | "Our R&D revenue during the three months ended March 31, 2026 included a $50 million milestone payment we earned when Roche initiated a Phase 1 trial for an investigational medicine for HD and $30 million in milestone payments we earned from GSK when regulatory filings for bepirovirsen were accepted for review in Japan and the European Union, or EU." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/874015/000087401526000177/form10q.htm)) |
| March 31, 2026 | [BRAINSTORM CELL THERAPEUTICS INC. earnings report](https://sec-api.dev/companies/bcli/catalysts) | BCLI |  | completed | "-- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the full year ended December 31, 2025, and provided a corporate update." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1137883/000110465926037760/tm2610751d1_ex99-1.htm)) |
| March 31, 2026 | [Tagrisso® (osimertinib) trial start](https://sec-api.dev/pdufa/osimertinib) | NVCT |  | completed | "Since our inception through March 31, 2026, our main activities have been organizational management,capital raising and the completion of the in-license agreements for, NXP800 and NXP900, regulatory filings with the Medicines and Healthcare products Regulatory Agency ("MHRA") and FDA, preparation and execution for the Phase 1a and Phase 1b clinical trial for NXP800, which commenced in December 2021 and May 2023, respectively, and Phase 1a, Phase 1b (single agent) and Phase 1b (combination study with osimertinib) clinical trials for NXP900, which commenced in September 2023, August 2025 and December 2025, respectively." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1875558/000110465926055318/tmb-20260331x10q.htm)) |
| March 31, 2026 | [Loncastuximab tesirine primary completion](https://sec-api.dev/pdufa/loncastuximab-tesirine) | ADCT | Relapsed Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma | completed | "NCT04384484 (Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-03-31 (ACTUAL); Lead Sponsor ADC Therapeutics S.A.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04384484)) |
| March 31, 2026 | [Itepekimab (sar440340) primary completion](https://sec-api.dev/pdufa/itepekimab-sar440340) | SNY | Chronic Rhinosinusitis Without Nasal Polyps | completed | "NCT06691113 (A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti--IL-33 mAb) in Participants With Chronic Rhinosinusitis Without Nasal Polyps): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-03-31 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06691113)) |

Other months: https://sec-api.dev/fda-calendar/2026-02 , https://sec-api.dev/fda-calendar/2026-04. Calendar: https://sec-api.dev/fda-calendar

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PDUFA dates March 2026: FDA calendar and catalysts." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/fda-calendar/2026-03

```bibtex
@misc{secapidev_fda_calendar_2026_03_20261116,
  title        = {PDUFA dates March 2026: FDA calendar and catalysts},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/fda-calendar/2026-03}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_fda_calendar_2026_03_20261116","title":"PDUFA dates March 2026: FDA calendar and catalysts","publisher":"sec-api.dev","URL":"https://sec-api.dev/fda-calendar/2026-03","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
